National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (No. PB 108 of 2010) (Cth)

PB 108 of 2010

National Health (Listing of Pharmaceutical Benefits) Instrument 2010

as amended

made under sections 84AF, 85, 85A, 88 and 101 of the

National Health Act 1953

This compilation was prepared on 1 September 2012
taking into account amendments up to PB 60 of 2012

This document has been split into two volumes
Volume 1 contains Sections 1–20 and Schedules 1–3
Volume 2 contains Schedule 4 and the Notes
Each volume has its own Table of Contents

Prepared by the Office of Legislative Drafting and Publishing,
Attorney-General’s Department, Canberra

Contents

1Name of Instrument [see Note 1]   3
2Commencement   3
3Revocation   3
4Definitions   3
5Drugs and medicinal preparations to which Part VII applies                   4
6Form   5
7Manner of administration   5
8Brand and responsible person   5
9Authorised prescriber   6
10Prescription circumstances — Schedule 1   6
11Authority required procedures   7
12Authority required procedures — submission of prescription                 7
13Authority required procedures — authorisation   8
14Streamlined authority code   9
15Prescription circumstances — Schedule 2   9
16Maximum quantity — Schedule 1   10
17Maximum quantity — Schedule 2   10
18Maximum number of repeats — Schedule 1   11
19Maximum number of repeats — Schedule 2   11
20Section 100 only supply   11

Schedule 1Ready-prepared pharmaceutical benefits 13

Schedule 2Extemporaneously-prepared pharmaceutical benefits 407

Part 1Listed drugs that may be used as ingredients in extemporaneously-prepared pharmaceutical benefits 407

Part 2Additives 409

Part 3Maximum quantity and number of repeats 409

Schedule 3Responsible person codes 410

Name of Instrument [see Note 1]

(1) This Instrument is the National Health (Listing of Pharmaceutical Benefits) Instrument 2010.

(2) This Instrument may also be cited as PB 108 of 2010.

Commencement

This Instrument commences on 1 December 2010.

3 Revocation

The following instruments are revoked:

(a) Declaration under subsections 85 (2) and 85 (2AA) of the National Health Act 1953; Determination under subsection 85 (2A) of the National Health Act 1953 (PB 14 of 2010);

(b) Determinations under sections 85, 85A and 88 of the National Health Act 1953 (PB 68 of 2010);

(c) Determination under section 84AF of the National Health Act 1953 (PB 69 of 2010);

(d) Determination under subsections 85A (1) and (2) and 88 (1C) of the National Health Act 1953 (PB 11 of 2009).

Definitions

In this Instrument:

ABN has the same meaning as in the A New Tax System (Australian Business Number) Act 1999.

Act means the National Health Act 1953.

authorised prescriber for a pharmaceutical benefit, means a kind of person identified by a prescriber code mentioned in the column in Schedule 1 headed ‘Authorised Prescriber’ for the benefit.

CFC means chlorofluorocarbon.

CFU means colony forming unit.

circumstances code means the letter ‘C’ followed by a number.

electronic communication has the meaning given by subsection 5 (1) of the Electronic Transactions Act 1999.

extemporaneously-prepared pharmaceutical benefit means a pharmaceutical benefit other than a ready-prepared pharmaceutical benefit.

General Statement for Lipid-Lowering Drugs means the statement set out in Part 2 of Schedule 4.

GP Management Plan means a comprehensive written plan for the treatment of a patient, prepared by a medical practitioner, that includes a description of the patient’s health care needs, management goals, actions to be taken by the patient and treatment and services the patient is likely to need.

I.M. means intramuscular.

I.U. means international unit.

I.V. mean intravenous.

mmol means millimole.

palliative care patient means a patient with an active, progressive, far-advanced disease for whom the prognosis is limited and the focus of care is the quality of life.

PBS means Pharmaceutical Benefits Scheme.

prescriber code means any of the following codes identifying the kind of person mentioned for the code:

(a) MP — medical practitioner;

(b) PDP — participating dental practitioner;

(c) AO — authorised optometrist;

(d) MW — authorised midwife;

(e) NP — authorised nurse practitioner.

purposes code means the letter ‘P’ followed by a number.

ready-prepared pharmaceutical benefit means a brand of a pharmaceutical item in relation to which a determination under subsection 85(6) of the Act is in force.

Regulations means the National Health (Pharmaceutical Benefits) Regulations 1960.

Streamlined Authority Code means the words ‘Streamlined Authority Code’ followed by a number.

Team Care Arrangements means a document prepared by a medical practitioner, following consultation with collaborating providers, that includes a description of the treatment and service goals for the patient, the treatment and services that all collaborating providers will provide and the actions to be taken by the patient.

Note Terms used in this Instrument have the same meaning as in the Act — see section 13 of the Legislative Instruments Act 2003. These terms include:

· Chief Executive Medicare

· pharmaceutical benefit

· pharmaceutical item.

Drugs and medicinal preparations to which Part VII applies

(1) For paragraph 85 (2) (a) of the Act, Part VII of the Act applies to:

(a) a drug or medicinal preparation mentioned in the column headed ‘Listed Drug’ in:

(i) Schedule 1; or

(ii) Part 1 of Schedule 2; and

(b) a medicinal preparation composed of 1 or more listed drugs mentioned in subparagraph (a) (ii).

(2) For subparagraph 85(2)(b)(i) of the Act, paragraph 85(2)(b) of the Act applies to a listed drug mentioned in subparagraph (1)(a)(ii).

(3) For subparagraph 85(2)(b)(ii) of the Act, paragraph 85(2)(b) of the Act applies to an additive mentioned in Part 2 of Schedule 2.

Note Part VII of the Act applies to medicinal preparations composed of 1 or more listed drugs mentioned in subsection (2) and 1 or more of the additives mentioned in subsection (3) – see paragraph 85(2)(b) of the Act.

Form

For subsection 85 (3) of the Act, the column headed ‘Form’ in Schedule 1 lists the form or forms for a listed drug determined for that drug.

Manner of administration

(1) For subsection 85 (5) of the Act, the manner of administration of a form of a listed drug mentioned in Schedule 1 is the manner of administration mentioned for that form of the drug in the column headed ‘Manner of Administration’ in Schedule 1.

(2) For paragraph 85A (2) (c) of the Act, if a manner of administration is mentioned in Schedule 1 for a form of a listed drug, a person writing a prescription for the supply of a pharmaceutical benefit that has the listed drug in that form must, if including a manner of administration in the prescription, direct that the pharmaceutical benefit be administered in that manner.

(3) For subsection (2), the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Brand and responsible person

(1) A brand mentioned in the column headed ‘Brand’ in Schedule 1 for a pharmaceutical item is determined for subsection 85 (6) of the Act for that pharmaceutical item.

(2) For subsection 84AF (1) of the Act, if a code is mentioned in the column in Schedule 1 headed ‘Responsible Person’ for a brand of a pharmaceutical item, the person mentioned in subsection (3) is the responsible person for the brand of the pharmaceutical item.

(3) For subsection (2), the person is the person mentioned in Schedule 3 for the code, with the ABN, if any, mentioned in Schedule 3 for the person.

(4) For subsections (1) and (2), the pharmaceutical item is the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Authorised prescriber

(1) For subsection 88 (1A) of the Act, a participating dental practitioner is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials PDP are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Schedule 1.

(2) For subsection 88 (1C) of the Act, an authorised optometrist is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials AO are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Schedule 1.

(3) For subsection 88 (1D) of the Act, an authorised midwife is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials MW are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Schedule 1.

(4) For subsection 88 (1E) of the Act, an authorised nurse practitioner is authorised to write a prescription for the supply of a pharmaceutical benefit if the initials NP are mentioned for the pharmaceutical benefit in the column headed ‘Authorised Prescriber’ in Schedule 1.

(5) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Note A medical practitioner may prescribe any pharmaceutical benefit — see subsection 88 (1) of the Act.

Prescription circumstances — Schedule 1

(1) This section applies to a pharmaceutical benefit if at least 1 circumstances code is mentioned in the column in Schedule 1 headed ‘Circumstances’ for the pharmaceutical benefit.

(2) For paragraph 85 (7) (a) of the Act, the pharmaceutical benefit is a relevant pharmaceutical benefit for the purposes of section 88A of the Act.

(3) For paragraph 85 (7) (b) of the Act, the circumstances in which a prescription for the supply of the pharmaceutical benefit may be written

are the circumstances mentioned in Part 1 of Schedule 4 for at least 1 of

the circumstances codes mentioned in Schedule 1 for the pharmaceutical benefit.

(4) For subsection (1), the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Authority required procedures

(1) This section applies to a pharmaceutical benefit if the circumstances mentioned in Part 1 of Schedule 4 for a circumstances code mentioned in Schedule 1 for the pharmaceutical benefit include any of the following:

(a) Compliance with Authority Required procedures;

(b) Compliance with Written Authority Required procedures;

(c) Compliance with Telephone Authority Required procedures;

(d) Compliance with Written or Telephone Authority Required procedures.

(2) A prescription for the supply of the pharmaceutical benefit must be:

(a) submitted by the authorised prescriber to the Chief Executive Medicare in accordance with section 12; and

(b) authorised by the Chief Executive Medicare in accordance with section 13.

Authority required procedures — submission of prescription

(1) The authorised prescriber must:

(a) deliver or post to the Chief Executive Medicare a prescription for the supply of the pharmaceutical benefit, prepared and signed by the authorised prescriber:

(i) in a form approved by the Secretary and completed by the authorised prescriber in ink in his or her own handwriting; or

(ii) in a form, prepared by means of a computer, that is in accordance with the form approved by the Secretary under subparagraph (i); or

(iii) in a form, prepared by means of a computer, approved in writing for the purpose by the Secretary and in the format approved in writing by the Secretary; or

(iv) by a method approved in writing by the Secretary; or

(b) submit to the Chief Executive Medicare, by telephone, details of a prescription for the supply of the pharmaceutical benefit prepared and signed by the authorised prescriber in accordance with subparagraph (a) (i), (ii), (iii) or (iv); or

(c) if the authorised prescriber has attempted give details of the prescription to the Chief Executive Medicare in accordance with paragraph (b) but has been unable to do so because the telephone system established by the Chief Executive Medicare for the provision of such authorisations was unavailable — submit the prescription in accordance with the instructions in an emergency telephone message provided to the authorised prescriber by the Chief Executive Medicare; or

(d) submit to the Chief Executive Medicare, by means of an electronic communication of a kind approved in writing by the Chief Executive Medicare, details of a prescription for the supply of the pharmaceutical benefit prepared and signed by the authorised prescriber in accordance with subparagraph (a) (i), (ii), (iii) or (iv).

(2) If a circumstance mentioned in Part 1 of Schedule 4 for a circumstances code applying to the pharmaceutical benefit includes Compliance with Written Authority Required procedures, the authorised prescriber must submit a prescription for the supply of the pharmaceutical benefit to the Chief Executive Medicare in accordance with paragraph (1) (a).

(3) If a circumstance mentioned in Part 1 of Schedule 4 for a circumstances code applying to the pharmaceutical benefit includes Compliance with Telephone Authority Required procedures, the authorised prescriber must submit a prescription for the supply of the pharmaceutical benefit to the Chief Executive Medicare in accordance with paragraph (1) (b) or (c).

(4) If a circumstance mentioned in Part 1 of Schedule 4 for a circumstances code applying to the pharmaceutical benefit includes Compliance with Written or Telephone Authority Required procedures, the authorised prescriber must submit a prescription for the supply of the pharmaceutical benefit to the Chief Executive Medicare in accordance with paragraph (1) (a), (b) or (c).

(5) For paragraph (1) (a), a prescription prepared and signed by the authorised prescriber in accordance with subsection (1) is taken to have been submitted by the authorised prescriber if it is submitted by his or her employee.

Authority required procedures — authorisation

(1) A prescription submitted in accordance with paragraph 12 (1) (a) may be authorised by the Chief Executive Medicare:

(a) signing his or her authorisation on the prescription; and

(b) either:

(i) if the Chief Executive Medicare requires the authorised prescriber to alter the prescription — returning it to the authorised prescriber for alteration before the authorised prescriber gives it to the person in respect of whom it was prepared; or

(ii) in any other case:

(A) returning the authorised prescription to the authorised prescriber; or

(B) sending it to the person in respect of whom it was prepared.

(2) A prescription submitted in accordance with paragraph 12 (1) (b) may be authorised by the Chief Executive Medicare telling the authorised prescriber by telephone, at the time the Chief Executive Medicare is given details of the prescription, that the prescription is authorised.

(3) A prescription submitted in accordance with paragraph 12 (1) (d) may be authorised by the Chief Executive Medicare sending his or her authorisation, by electronic communication, to the authorised prescriber.

(4) If the Chief Executive Medicare authorises a prescription under subsection (2) or (3):

(a) the Chief Executive Medicare must tell the authorised prescriber the number given by the Chief Executive Medicare to the prescription: and

(b) the authorised prescriber must:

(i) mark that number on the prescription; and

(ii) retain a copy of the prescription for 1 year from the date the prescription was authorised.

(5) For paragraph (4) (a), the Chief Executive Medicare must tell the authorised prescriber the number:

(i) if the authorised prescriber is an authorised optometrist — by telephone; and

(ii) in any other case — by telephone or by electronic communication.

(6) A prescription submitted in accordance with paragraph 12 (1) (c) is taken to have been authorised by the Chief Executive Medicare if the authorised prescriber completes the prescription in accordance with the instructions given in the emergency telephone message.

Streamlined authority code

(1) This section applies to a pharmaceutical benefit if the circumstances mentioned in Schedule 4 for a circumstances code applying to the pharmaceutical benefit include a Streamlined Authority Code.

(2) The requirements of section 12 are taken to have been complied with, and the Chief Executive Medicare is taken to have authorised the prescription of the pharmaceutical benefit under section 13, if the authorised prescriber has:

(a) prepared and signed a prescription for the supply of the pharmaceutical benefit in accordance with subparagraph 12 (1) (a) (i), (ii), (iii) or (iv); and

(b) written the Streamlined Authority Code on the prescription.

Prescription circumstances — Schedule 2

(1) For paragraph 85 (7) (a) of the Act, a pharmaceutical benefit is a relevant pharmaceutical benefit for the purposes of section 88A if:

(a) it is:

(i) a listed drug mentioned in Part 1 of Schedule 2; or

(ii) an extemporaneously-prepared pharmaceutical benefit that contains the listed drug; and

(b) there are circumstances mentioned for the listed drug in the column headed ‘Circumstances’ in Part 1 of Schedule 2.

(2) For paragraph 85 (7) (b) of the Act, the circumstances in which a prescription for the supply of a pharmaceutical benefit mentioned in subsection (1) may be written are:

(a) for a listed drug mentioned in subparagraph (1) (a) (i) — the circumstances mentioned in the column headed ‘Circumstances’ in Part 1 of Schedule 2 for the drug; and

(b) for an extemporaneously-prepared pharmaceutical benefit mentioned in subparagraph (1) (a) (ii) — the circumstances mentioned in the column headed ‘Circumstances’ in Part 1 of Schedule 2 for each listed drug contained in the pharmaceutical benefit.

Note If an extemporaneously-prepared pharmaceutical benefit contains more than one listed drug, a prescription for the supply of the pharmaceutical benefit may only be written if the circumstances mentioned for each of the listed drugs contained in the pharmaceutical benefit are met.

Maximum quantity — Schedule 1

(1) For paragraph 85A (2) (a) of the Act, the maximum quantity or number of units of the pharmaceutical item in a pharmaceutical benefit mentioned in Schedule 1 that may, in 1 prescription for the supply of the pharmaceutical benefit, be directed by an authorised prescriber to be supplied on any 1 occasion is the quantity or number of units mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ for the pharmaceutical benefit and authorised prescriber.

(2) If at least 1 purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’ for a pharmaceutical benefit, the quantity or number of units mentioned in the column headed ‘Maximum Quantity’ is the maximum for the particular purposes mentioned in Schedule 4 for each purposes code.

(3) If no purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’, the quantity or number of units mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ is the maximum for all purposes, other than a purpose for which a different maximum is mentioned for the same pharmaceutical benefit.

(4) For subsection (1) the pharmaceutical item is the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

(5) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Maximum quantity — Schedule 2

(1) For paragraph 85A (2) (a) of the Act, the maximum quantity or number of units of an extemporaneously-prepared pharmaceutical benefit of a type mentioned in Part 3 of Schedule 2 that may, in 1 prescription for the supply of the pharmaceutical benefit, be directed by an authorised prescriber to be supplied on any 1 occasion is the quantity or number of units mentioned in the column headed ‘Maximum Quantity’ in Part 3 of Schedule 2 for that type of pharmaceutical benefit.

(2) For subsection (1), the extemporaneously-prepared pharmaceutical benefit is:

(a) the listed drug mentioned in Part 1 of Schedule 2; or

(b) an extemporaneously-prepared pharmaceutical benefit that contains the listed drug.

Maximum number of repeats — Schedule 1

(1) For paragraph 85A (2) (b) of the Act, the maximum number of occasions an authorised prescriber may, in 1 prescription, direct that the supply of a pharmaceutical benefit mentioned in Schedule 1 be repeated is the number in the column in Schedule 1 headed ‘Number of Repeats’ for the pharmaceutical benefit and the authorised prescriber.

(2) If at least 1 purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’ for the pharmaceutical benefit, the number of repeats mentioned in the column in Schedule 1 headed ‘Number of Repeats’ is the maximum for the particular purposes mentioned in Schedule 4 for each purposes code.

(3) If no purposes code is mentioned in the column headed ‘Purposes’, the number of repeats mentioned in the column headed ‘Number of Repeats’ is the maximum for all purposes, other than a purpose for which a different maximum is mentioned for the same pharmaceutical benefit.

(4) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Maximum number of repeats — Schedule 2

(1) For paragraph 85A (2) (b) of the Act, the maximum number of occasions an authorised prescriber may, in 1 prescription, direct that the supply of an extemporaneously-prepared pharmaceutical benefit of a type mentioned in Part 3 of Schedule 2 be repeated is the number in the column headed ‘Number of Repeats’ in Part 3 of Schedule 2 for that type of pharmaceutical benefit.

(2) For this section, the extemporaneously-prepared pharmaceutical benefit is:

(a) the listed drug mentioned in Part 1 of Schedule 2; or

(b) an extemporaneously-prepared pharmaceutical benefit that contains the listed drug.

Section 100 only supply

(1) For subsection 85 (2A) of the Act, if the letter D is mentioned in the column headed ‘Section 100 only’ in Schedule 1 for a listed drug, the drug can only be supplied under special arrangements under section 100 of the Act.

(2) For paragraph 85 (8) (a) of the Act, if the letters PB are mentioned in the column headed ‘Section 100 only’ in Schedule 1 for a pharmaceutical benefit, the pharmaceutical benefit can only be supplied under special arrangements under section 100 of the Act.

(3) For paragraph 85 (8) (b) of the Act, if the letter C is mentioned in the column headed ‘Section 100 only’ in Schedule 1 for a pharmaceutical benefit, and a circumstances code is mentioned for the pharmaceutical benefit in the column headed ‘Circumstances’, the pharmaceutical benefit can be supplied in the circumstances identified in Part 1 of Schedule 4 for the circumstances code only under special arrangements under section 100 of the Act.

(4) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Schedule 1 Ready-prepared pharmaceutical benefits

(sections 5 to 10, 16, 18 and 20)

Listed Drug	Form	Manner of Administration	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Max Quantity	Number of Repeats	Section 100 only
Abacavir	Tablet 300 mg (as sulfate)	Oral	Ziagen	VI	MP See Note 1	C3586 C3587 C3588 C 3589	120	5	D
Oral solution 20 mg (as sulfate) per mL, 240 mL	Oral	Ziagen	VI	MP See Note 1	C3586 C3587 C3588 C3589	8	5	D
Abacavir with Lamivudine	Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg	Oral	Kivexa	VI	MP See Note 1	C3590 C3591 C3592 C3593	60	5	D
Abacavir with Lamivudine and Zidovudine	Tablet containing abacavir 300 mg (as sulfate) with lamivudine 150 mg and zidovudine 300 mg	Oral	Trizivir	VI	MP See Note 1	C3979 C3980 C3981 C3982	120	5	D
Abatacept	Injection 125 mg in 1 mL single dose pre-filled syringe	Injection	Orencia	BQ	MP	C3996 C3997 C3998	P3996 C3997	4	3
MP	C3996 C3997 C3998	P3998	4	5
Powder for I.V. infusion 250 mg	Injection	Orencia	BQ	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	PB
Abciximab	I.V. injection 10 mg in 5 mL vial	Injection	ReoPro	LY	MP	C1716 C1717 C1718	3	0
Acamprosate	Tablet (enteric coated) containing acamprosate calcium 333 mg	Oral	Campral	AF	MP NP	C2665	180	1
Acarbose	Tablet 50 mg	Oral	Glucobay 50	BN	MP NP	90	5
Tablet 100 mg	Oral	Glucobay 100	BN	MP NP	90	5
Acetazolamide	Tablet 250 mg	Oral	Diamox	QA	MP NP	100	3
Aciclovir	Tablet 200 mg	Oral	Acihexal	SZ	MP NP	C3632 C3633	P3632	50	0
Acyclo-V 200	AF	MP NP	C3632 C3633	P3632	50	0
GenRx Aciclovir	GX	MP NP	C3632 C3633	P3632	50	0
Lovir	GM	MP NP	C3632 C3633	P3632	50	0
Zovirax 200 mg	GK	MP NP	C3632 C3633	P3632	50	0
Aciclovir 200	CR	MP NP	C3633	P3633	90	5
Aciclovir GH	GQ	MP NP	C3633	P3633	90	5
Acihexal	SZ	MP NP	C3632 C3633	P3633	90	5
Acyclo-V 200	AF	MP NP	C3632 C3633	P3633	90	5
Chem mart Aciclovir	CH	MP NP	C3633	P3633	90	5
GenRx Aciclovir	GX	MP NP	C3632 C3633	P3633	90	5
Lovir	GM	MP NP	C3632 C3633	P3633	90	5
Ozvir	RA	MP NP	C3633	P3633	90	5
Terry White Chemists Aciclovir	TW	MP NP	C3633	P3633	90	5
Zovirax 200 mg	GK	MP NP	C3632 C3633	P3633	90	5
Tablet 800 mg	Oral	Aciclovir 800	CR	MP NP	C3622 C3631	P3622 P3631	35	0
Acihexal	SZ	MP NP	C3622 C3630 C3631	P3622 P3631	35	0
Acyclo-V 800	AF	MP NP	C3622 C3630 C3631	P3622 P3631	35	0
GenRx Aciclovir	GX	MP NP	C3622 C3631	P3622 P3631	35	0
Zovirax 800 mg	GK	MP NP	C3622 C3631	P3622 P3631	35	0
Acihexal	SZ	MP NP	C3622 C3630 C3631	P3630	120	5
Acyclo-V 800	AF	MP NP	C3622 C3630 C3631	P3630	120	5
Eye ointment 30 mg per g, 4.5 g	Application to the eye	Zovirax	GK	MP NP AO	C1715	1	0
Acitretin	Capsule 10 mg	Oral	Neotigason	TA	MP	C1363 C1366	100	2
Capsule 25 mg	Oral	Neotigason	TA	MP	C1363 C1366	100	2
Adalimumab	Injection 20 mg in 0.4 mL pre-filled syringe	Injection	Humira	VE	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	PB
Injection 40 mg in 0.8 mL pre-filled syringe	Injection	Humira	VE	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	C
MP	C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761	P2986 P2990 P2993 P3695 P3747 P3753 P3754	2	2
MP	C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761	P3486 P3502 P3520 P3706 P3743 P3745 P3749 P3751	2	3
MP	C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761	P3265 P3267 P3758 P3759	2	4
MP	C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761	P2988 P2995 P3522 P3697 P3744 P3746 P3748 P3750 P3752 P3755 P3756 P3757 P3760 P3761	2	5
Injection 40 mg in 0.8 mL pre-filled pen	Injection	Humira	VE	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	C
MP	C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761	P2986 P2990 P2993 P3695 P3747 P3753 P3754	2	2
MP	C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761	P3486 P3502 P3520 P3706 P3743 P3745 P3749 P3751	2	3
MP	C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761	P3265 P3267 P3758 P3759	2	4
MP	C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761	P2988 P2995 P3522 P3697 P3744 P3746 P3748 P3750 P3752 P3755 P3756 P3757 P3760 P3761	2	5
Injection 40 mg in 0.8 mL pre-filled syringe, 6	Injection	Humira	VE	MP	C2986 C2990 C2993 C3695 C3747 C3753 C3754	1	0
Injection 40 mg in 0.8 mL pre-filled pen, 6	Injection	Humira	VE	MP	C2986 C2990 C2993 C3695 C3747 C3753 C3754	1	0
Adapalene with benzoyl peroxide	Gel 1 mg-25 mg per g, 30 g	Application	Epiduo	GA	MP	C3689 C3690	P3689	1	1
MP	C3689 C3690	P3690	1	3
NP	C3690	1	3
Adefovir	Tablet containing adefovir dipivoxil 10 mg	Oral	Hepsera	GI	MP See Note 1	C3971 C3972 C3973 C3974	60	5	D
Adrenaline	Injection 1 mg (as acid tartrate) in 1 mL (1 in 1,000)	Injection	Link Medical Products Pty Ltd	LM	PDP	5	0
MP NP	5	1
I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector (EpiPen Jr.)	Injection	EpiPen Jr.	AL	MP NP	C3434 C3435 C3436	1	0
I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector (Anapen Junior)	Injection	Anapen Junior	LM	MP NP	C3434 C3435 C3436	1	0
I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector (EpiPen)	Injection	EpiPen	AL	MP NP	C3434 C3435 C3436	1	0
I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector (Anapen)	Injection	Anapen	LM	MP NP	C3434 C3435 C3436	1	0
Albendazole	Tablet 200 mg	Oral	Zentel	GK	MP NP	C1388 C1525 C2446 C3241	P1388 P2446 P3241	6	0
MP NP	C1388 C1525 C2446 C3241	P1525	6	1
Tablet 400 mg	Oral	Eskazole	GK	MP	C1496	60	2
Alendronic Acid	Tablet 70 mg (as alendronate sodium)	Oral	Adronat	AF	MP NP	C2646 C3070 C3933	4	5
Alendrobell 70mg	GQ	MP NP	C2646 C3070 C3933	4	5
Alendronate-GA	GM	MP NP	C2646 C3070 C3933	4	5
Alendronate Sandoz	SZ	MP NP	C2646 C3070 C3933	4	5
Alendro Once Weekly	QA	MP NP	C2646 C3070 C3933	4	5
APO-Alendronate	TX	MP NP	C2646 C3070 C3933	4	5
Chem mart Alendronate 70mg	CH	MP NP	C2646 C3070 C3933	4	5
Densate 70	DO	MP NP	C2646 C3070 C3933	4	5
Fosamax Once Weekly	MK	MP NP	C2646 C3070 C3933	4	5
Ossmax 70mg	RA	MP NP	C2646 C3070 C3933	4	5
Terry White Chemists Alendronate 70mg	TW	MP NP	C2646 C3070 C3933	4	5
Tablet 40 mg (as alendronate sodium)	Oral	Fosamax 40 mg	MK	MP NP	C3256	30	5
Alendronic acid with colecalciferol	Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol	Oral	Fosamax Plus	MK	MP NP	C2646 C3070 C3933	4	5
Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol	Oral	Dronalen Plus	GM	MP NP	C2646 C3070 C3933	4	5
Fosamax Plus 70 mg/140 mcg	MK	MP NP	C2646 C3070 C3933	4	5
Alendronic acid with colecalciferol and calcium	Pack containing 4 tablets containing alendronic acid 70 mg (as alendronate sodium) with 140 micrograms colecalciferol and 48 tablets calcium 500 mg (as carbonate)	Oral	Dronalen Plus D-Cal	FR	MP NP	C2646 C3070 C3933	1	5
Fosamax Plus D-Cal	MK	MP NP	C2646 C3070 C3933	1	5
Alginic acid with calcium carbonate and sodium bicarbonate	Oral liquid containing alginic acid as sodium alginate 1 g, calcium carbonate 320 mg and sodium bicarbonate 534 mg in 20 mL, 500 mL	Oral	Gaviscon P	RC	MP NP	2	5
Allopurinol	Tablet 100 mg	Oral	Allopurinol Sandoz	SZ	MP NP	200	2
Allosig	FM	MP NP	200	2
Chem mart Allopurinol	CH	MP NP	200	2
GenRx Allopurinol	GX	MP NP	200	2
Progout 100	AF	MP NP	200	2
Terry White Chemists Allopurinol	TW	MP NP	200	2
Zyloprim	QA	MP NP	200	2
Tablet 300 mg	Oral	Allopurinol Sandoz	SZ	MP NP	60	2
Allosig	FM	MP NP	60	2
Chem mart Allopurinol	CH	MP NP	60	2
GenRx Allopurinol	GX	MP NP	60	2
Progout 300	AF	MP NP	60	2
Terry White Chemists Allopurinol	TW	MP NP	60	2
Zyloprim	QA	MP NP	60	2
Alprazolam	Tablet 250 micrograms	Oral	Alprax 0.25	QA	MP NP	C1975	50	0
Alprazolam Sandoz	SZ	MP NP	C1975	50	0
Kalma 0.25	AF	MP NP	C1975	50	0
Xanax	PF	MP NP	C1975	50	0
Tablet 500 micrograms	Oral	Alprax 0.5	QA	MP NP	C1975	50	0
Alprazolam Sandoz	SZ	MP NP	C1975	50	0
Kalma 0.5	AF	MP NP	C1975	50	0
Xanax	PF	MP NP	C1975	50	0
Tablet 1 mg	Oral	Alprax 1	QA	MP NP	C1975	50	2
Alprazolam Sandoz	SZ	MP NP	C1975	50	2
Chem mart Alprazolam	CH	MP NP	C1975	50	2
GenRx Alprazolam	GX	MP NP	C1975	50	2
Kalma 1	AF	MP NP	C1975	50	2
Ralozam	GM	MP NP	C1975	50	2
Terry White Chemists Alprazolam	TW	MP NP	C1975	50	2
Xanax	PF	MP NP	C1975	50	2
Tablet 2 mg	Oral	Alprax 2	QA	MP NP	C1975	50	2
Alprazolam Sandoz	SZ	MP NP	C1975	50	2
Chem mart Alprazolam	CH	MP NP	C1975	50	2
GenRx Alprazolam	GX	MP NP	C1975	50	2
Kalma 2	AF	MP NP	C1975	50	2
Ralozam	GM	MP NP	C1975	50	2
Terry White Chemists Alprazolam	TW	MP NP	C1975	50	2
Xanax Tri-Score	PF	MP NP	C1975	50	2
Aluminium Hydroxide with Magnesium Hydroxide	Oral suspension 200 mg-200 mg per 5 mL, 500 mL	Oral	Mylanta P	JT	MP NP	2	5
Aluminium Hydroxide with Magnesium Trisilicate and Magnesium Hydroxide	Oral suspension 250 mg-120 mg-120 mg per 5 mL, 500 mL	Oral	Gastrogel	FM	MP NP	2	5
Amantadine	Capsule containing amantadine hydrochloride 100 mg	Oral	Symmetrel 100	NV	MP NP	C1258	100	5
Ambrisentan	Tablet 5 mg	Oral	Volibris	GK	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Tablet 10 mg	Oral	Volibris	GK	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Amino acid formula with fat, carbohydrate, vitamins, minerals, and trace elements, without methionine and supplemented with docosahexanoic acid	Oral liquid 125 mL, 36 (HCU Anamix junior LQ)	Oral	HCU Anamix junior LQ	SB	MP NP	C1314	4	5
Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine, and supplemented with docosahexanoic acid	Oral liquid 125 mL, 36 (TYR Anamix junior LQ)	Oral	TYR Anamix junior LQ	SB	MP NP	C1453	4	5
Amino acid formula without phenylalanine	Capsules 500 mg, 200 (Phlexy-10)	Oral	Phlexy-10	SB	MP NP	C1286	16	5
Tablets 1 g, 75 (Phlexy-10)	Oral	Phlexy-10	SB	MP NP	C1286	24	5
Sachets containing oral powder 20 g, 30 (Phlexy-10 Drink Mix)	Oral	Phlexy-10 Drink Mix	SB	MP NP	C1286	7	5
Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine	Oral powder 400 g (PKU Anamix infant)	Oral	PKU Anamix infant	SB	MP NP	C1286	8	5
Amino acid formula with vitamins and minerals without lysine and low in tryptophan	Sachets containing oral powder 24 g, 30 (GA gel)	Oral	GA gel	VF	MP NP	C3134	4	5
Oral powder 400 g (GA1 Anamix infant)	Oral	GA1 Anamix infant	SB	MP NP	C2612	8	5
Oral powder 500 g (XLYS, LOW TRY Maxamaid)	Oral	XLYS, LOW TRY Maxamaid	SB	MP NP	C3550	8	5
Sachets containing oral powder 25 g, 30 (GA express 15)	Oral	GA express 15	VF	MP NP	C3678	4	5
Amino acid formula with vitamins and minerals without methionine	Oral powder 400 g (HCU Anamix infant)	Oral	HCU Anamix infant	SB	MP NP	C1484	8	5
Sachets containing oral powder 24 g, 30 (HCU gel)	Oral	HCU gel	VF	MP NP	C1314	4	5
Sachets containing oral powder 25 g, 30 (HCU express 15)	Oral	HCU express 15	VF	MP NP	C1314	4	5
Oral powder 500 g (XMET Maxamaid)	Oral	XMET Maxamaid	SB	MP NP	C1314	8	5
Oral powder 500 g (XMET Maxamum)	Oral	XMET Maxamum	SB	MP NP	C1314	8	5
Oral liquid 125 mL, 30 (HCU Lophlex LQ 20)	Oral	HCU Lophlex LQ 20	SB	MP NP	C1314	3	5
Oral liquid 130 mL, 30 (HCU Cooler)	Oral	HCU Cooler	VF	MP NP	C1314	4	5
Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine	Sachets containing oral powder 25 g, 30 (MMA/PA express 15)	Oral	MMA/PA express 15	VF	MP NP	C1225 C1307	4	5
Sachets containing oral powder 24 g, 30 (MMA/PA gel)	Oral	MMA/PA gel	VF	MP NP	C1225 C1307	4	5
Oral powder 400 g (MMA/PA Anamix infant)	Oral	MMA/PA Anamix infant	SB	MP NP	C1225 C1307	8	5
Oral powder 500 g (XMTVI Maxamaid)	Oral	XMTVI Maxamaid	SB	MP NP	C1225 C1307	8	5
Oral powder 500 g (XMTVI Maxamum)	Oral	XMTVI Maxamum	SB	MP NP	C1225 C1307	8	5
Oral liquid 130 mL, 30 (MMA/PA cooler)	Oral	MMA/PA cooler	VF	MP NP	C1225 C1307	4	5
Amino acid formula with vitamins and minerals without phenylalanine	Sachets containing oral powder 18.2 g, 60 (add-ins)	Oral	add-ins	SB	MP NP	C1286	3	5
Sachets containing oral powder 24 g, 30 (PKU gel)	Oral	PKU gel	VF	MP NP	C1286	4	5
Sachets containing oral powder 25 g, 30 (PKU express 15)	Oral	PKU express 15	VF	MP NP	C1286	4	5
Sachets containing oral powder 27.8 g, 30 (Lophlex)	Oral	Lophlex	SB	MP NP	C1286	3	5
Sachets containing oral powder 29 g, 30 (PKU Anamix Junior)	Oral	PKU Anamix Junior	SB	MP NP	C1286	4	5
Sachets containing oral powder 34 g, 30 (PKU express 20)	Oral	PKU express 20	VF	MP NP	C1286	4	5
Sachets containing oral powder 50 g, 30 (XP Maxamum)	Oral	XP Maxamum	SB	MP NP	C1286	3	5
Oral gel 85 g, 30 (PKU squeezie)	Oral	PKU squeezie	VF	MP NP	C1286	4	5
Oral powder 400 g (Phenex-2)	Oral	Phenex-2	AB	MP NP	C1286	8	5
Oral powder 500 g (XP Maxamaid)	Oral	XP Maxamaid	SB	MP NP	C1286	8	5
Oral powder 500 g (XP Maxamum)	Oral	XP Maxamum	SB	MP NP	C1286	8	5
Oral liquid 250 mL (Easiphen)	Oral	Easiphen	SB	MP NP	C1286	90	5
Oral liquid 62.5 mL, 60 (PKU Lophlex LQ 10)	Oral	PKU Lophlex LQ 10	SB	MP NP	C1286	2	5
Oral liquid 87 mL, 30 (PKU Cooler 10)	Oral	PKU Cooler 10	VF	MP NP	C1286	4	5
Oral liquid 125 mL, 30 (PKU Lophlex LQ 20)	Oral	PKU Lophlex LQ 20	SB	MP NP	C1286	3	5
Oral liquid 125 mL, 36 (PKU Anamix Junior LQ)	Oral	PKU Anamix Junior LQ	SB	MP NP	C1286	4	5
Oral liquid 130 mL, 30 (PKU Cooler 15)	Oral	PKU Cooler 15	VF	MP NP	C1286	4	5
Oral liquid 174 mL, 30 (PKU Cooler 20)	Oral	PKU Cooler 20	VF	MP NP	C1286	4	5
Amino acid formula with vitamins and minerals without phenylalanine and tyrosine	Sachets containing oral powder 24 g, 30 (TYR gel)	Oral	TYR gel	VF	MP NP	C1453	4	5
Sachets containing oral powder 25 g, 30 (TYR express 15)	Oral	TYR express 15	VF	MP NP	C1453	4	5
Sachets containing oral powder 29 g, 30 (TYR Anamix Junior)	Oral	TYR Anamix Junior	SB	MP NP	C1453	4	5
Oral powder 400 g (TYR Anamix infant)	Oral	TYR Anamix infant	SB	MP NP	C1453	8	5
Oral powder 500 g (XPhen, Tyr Maxamaid)	Oral	XPhen, Tyr Maxamaid	SB	MP NP	C1453	8	5
Oral powder 500 g (XPhen, Tyr Maxamum)	Oral	XPhen, Tyr Maxamum	SB	MP NP	C1453	8	5
Oral liquid 125 mL, 30 (TYR Lophlex LQ 20)	Oral	TYR Lophlex LQ 20	SB	MP NP	C1453	3	5
Oral liquid 130 mL, 30 (TYR Cooler)	Oral	TYR Cooler	VF	MP NP	C1453	4	5
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine	Sachets containing oral powder 24 g, 30 (MSUD gel)	Oral	MSUD gel	VF	MP NP	C1220	4	5
Sachets containing oral powder 25 g, 30 (MSUD express 15)	Oral	MSUD express 15	VF	MP NP	C1220	4	5
Sachets containing oral powder 29 g, 30 (MSUD Anamix Junior)	Oral	MSUD Anamix Junior	SB	MP NP	C1220	4	5
Sachets containing oral powder 34 g, 30 (MSUD express 20)	Oral	MSUD express 20	VF	MP NP	C1220	4	5
Oral powder 400 g (MSUD Anamix infant)	Oral	MSUD Anamix infant	SB	MP NP	C1220	8	5
Oral powder 500 g (MSUD AID III)	Oral	MSUD AID III	SB	MP NP	C1220	4	5
Oral powder 500 g (MSUD Maxamaid)	Oral	MSUD Maxamaid	SB	MP NP	C1220	8	5
Oral powder 500 g (MSUD Maxamum)	Oral	MSUD Maxamum	SB	MP NP	C1220	8	5
Oral liquid 125 mL, 30 (MSUD Lophlex LQ 20)	Oral	MSUD Lophlex LQ 20	SB	MP NP	C1220	3	5
Oral liquid 130 mL, 30 (MSUD Cooler)	Oral	MSUD Cooler	VF	MP NP	C1220	4	5
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine with fat, carbohydrate and trace elements and supplemented with docosahexanoic acid	Oral liquid 125 mL, 36 (MSUD Anamix Junior LQ)	Oral	MSUD Anamix Junior LQ	SB	MP NP	C1220	4	5
Amino acids — synthetic, formula	Oral powder 400 g (EleCare)	Oral	EleCare	AB	MP NP	C1687 C1688 C2734 C2735 C4033 C4034 C4035 C4036 C4037 C4038 C4039	P1687 P1688 P4033 P4034 P4035 P4036 P4037 P4038 P4039	8	5
MP NP	C1687 C1688 C2734 C2735 C4033 C4034 C4035 C4036 C4037 C4038 C4039	P2734 P2735	12	5
Oral powder 400 g (Neocate Advance)	Oral	Neocate Advance	SB	MP NP	C1687 C1688 C4033 C4034 C4035 C4036 C4037 C4038 C4039	8	5
Oral powder 400 g (Neocate Advance Tropical Flavour)	Oral	Neocate Advance Tropical Flavour	SB	MP NP	C1687 C1688 C4033 C4034 C4035 C4036 C4037 C4038 C4039	8	5
Oral powder 400 g (Neocate Advance Vanilla)	Oral	Neocate Advance Vanilla	SB	MP NP	C1687 C1688 C2734 C2735 C4033 C4034 C4035 C4036 C4037 C4038 C4039	P1687 P1688 P4033 P4034 P4035 P4036 P4037 P4038 P4039	8	5
MP NP	C1687 C1688 C2734 C2735 C4033 C4034 C4035 C4036 C4037 C4038 C4039	P2734 P2735	12	5
Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids	Oral powder 400 g (Neocate LCP)	Oral	Neocate LCP	SB	MP NP	C1687 C1688 C4033 C4034 C4035 C4036 C4037 C4038 C4039	8	5
Oral powder 400 g (EleCare LCP)	Oral	EleCare LCP	AB	MP NP	C1687 C1688 C4033 C4034 C4035 C4036 C4037 C4038 C4039	8	5
Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides	Oral powder 400 g (Neocate Gold)	Oral	Neocate Gold	SB	MP NP	C1687 C1688 C2734 C2735 C4033 C4034 C4035 C4036 C4037 C4038 C4039	P1687 P1688 P4033 P4034 P4035 P4036 P4037 P4038 P4039	8	5
MP NP	C1687 C1688 C2734 C2735 C4033 C4034 C4035 C4036 C4037 C4038 C4039	P2734 P2735	12	5
Amiodarone	Tablet containing amiodarone hydrochloride 100 mg	Oral	Amiodarone Sandoz	SZ	MP NP	C1350	30	5
Aratac 100	AF	MP NP	C1350	30	5
Cordarone X 100	SW	MP NP	C1350	30	5
Tablet containing amiodarone hydrochloride 200 mg	Oral	Amiodarone Sandoz	SZ	MP NP	C1350	30	5
Aratac 200	AF	MP NP	C1350	30	5
Chem mart Amiodarone	CH	MP NP	C1350	30	5
Cordarone X 200	SW	MP NP	C1350	30	5
GenRx Amiodarone	GX	MP NP	C1350	30	5
Rithmik 200	QA	MP NP	C1350	30	5
Terry White Chemists Amiodarone	TW	MP NP	C1350	30	5
Amisulpride	Tablet 100 mg	Oral	Amisulpride 100 Winthrop	WA	MP NP	C1589	30	5
Amisulpride Sandoz	SZ	MP NP	C1589	30	5
APO-Amisulpride	TX	MP NP	C1589	30	5
Solian 100	SW	MP NP	C1589	30	5
Sulprix	AF	MP NP	C1589	30	5
Tablet 200 mg	Oral	Amisulpride 200 Winthrop	WA	MP NP	C1589	60	5
Amisulpride Sandoz	SZ	MP NP	C1589	60	5
APO-Amisulpride	TX	MP NP	C1589	60	5
Solian 200	SW	MP NP	C1589	60	5
Sulprix	AF	MP NP	C1589	60	5
Tablet 400 mg	Oral	Amipride 400	QA	MP NP	C1589	60	5
Amisulpride 400 Winthrop	WA	MP NP	C1589	60	5
Amisulpride Sandoz	SZ	MP NP	C1589	60	5
APO-Amisulpride	TX	MP NP	C1589	60	5
Solian 400	SW	MP NP	C1589	60	5
Sulprix	AF	MP NP	C1589	60	5
Oral solution 100 mg per mL, 60 mL	Oral	Solian Solution	SW	MP NP	C1589	2	5
Amitriptyline	Tablet containing amitriptyline hydrochloride 10 mg	Oral	Endep 10	AF	MP NP	50	2
Tablet containing amitriptyline hydrochloride 25 mg	Oral	Endep 25	AF	MP NP	50	2
Tablet containing amitriptyline hydrochloride 50 mg	Oral	Endep 50	AF	MP NP	50	2
Amlodipine	Tablet 5 mg (as besylate)	Oral	Amlodipine-DRLA	RZ	MP NP	30	5
Amlodipine-GA	GM	MP NP	30	5
Amlodipine generichealth	GQ	MP NP	30	5
Amlodipine Pfizer	FZ	MP NP	30	5
Amlodipine Sandoz	SZ	MP NP	30	5
APO-Amlodipine	TX	MP NP	30	5
Auro-Amlodipine 5	DO	MP NP	30	5
Chem mart Amlodipine	CH	MP NP	30	5
Nordip	AF	MP NP	30	5
Norvapine	GN	MP NP	30	5
Norvasc	PF	MP NP	30	5
Ozlodip	RA	MP NP	30	5
Pharmacor Amlodipine 5	CR	MP NP	30	5
Terry White Chemists Amlodipine	TW	MP NP	30	5
Tablet 5 mg (as maleate)	Oral	Amlo 5	ZP	MP NP	30	5
Tablet 10 mg (as besylate)	Oral	Amlodipine-DRLA	RZ	MP NP	30	5
Amlodipine-GA	GM	MP NP	30	5
Amlodipine generichealth	GQ	MP NP	30	5
Amlodipine Pfizer	FZ	MP NP	30	5
Amlodipine Sandoz	SZ	MP NP	30	5
APO-Amlodipine	TX	MP NP	30	5
Auro-Amlodipine 10	DO	MP NP	30	5
Chem mart Amlodipine	CH	MP NP	30	5
Nordip	AF	MP NP	30	5
Norvapine	GN	MP NP	30	5
Norvasc	PF	MP NP	30	5
Ozlodip	RA	MP NP	30	5
Pharmacor Amlodipine 10	CR	MP NP	30	5
Terry White Chemists Amlodipine	TW	MP NP	30	5
Tablet 10 mg (as maleate)	Oral	Amlo 10	ZP	MP NP	30	5
Amlodipine with Atorvastatin	Tablet 5 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium)	Oral	Cadatin 5/10	FZ	MP NP	C2449 C2450 C2451	30	5
Caduet 5/10	PF	MP NP	C2449 C2450 C2451	30	5
Tablet 5 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium)	Oral	Cadatin 5/20	FZ	MP NP	C2449 C2450 C2451	30	5
Caduet 5/20	PF	MP NP	C2449 C2450 C2451	30	5
Tablet 5 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium)	Oral	Cadatin 5/40	FZ	MP NP	C2449 C2450 C2451	30	5
Caduet 5/40	PF	MP NP	C2449 C2450 C2451	30	5
Tablet 5 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium)	Oral	Cadatin 5/80	FZ	MP NP	C2449 C2450 C2451	30	5
Caduet 5/80	PF	MP NP	C2449 C2450 C2451	30	5
Tablet 10 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium)	Oral	Cadatin 10/10	FZ	MP NP	C2449 C2450 C2451	30	5
Caduet 10/10	PF	MP NP	C2449 C2450 C2451	30	5
Tablet 10 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium)	Oral	Cadatin 10/20	FZ	MP NP	C2449 C2450 C2451	30	5
Caduet 10/20	PF	MP NP	C2449 C2450 C2451	30	5
Tablet 10 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium)	Oral	Cadatin 10/40	FZ	MP NP	C2449 C2450 C2451	30	5
Caduet 10/40	PF	MP NP	C2449 C2450 C2451	30	5
Tablet 10 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium)	Oral	Cadatin 10/80	FZ	MP NP	C2449 C2450 C2451	30	5
Caduet 10/80	PF	MP NP	C2449 C2450 C2451	30	5
Amlodipine with valsartan	Tablet 5 mg (as besylate)-80 mg	Oral	Exforge 5/80	NV	MP NP	C3307	28	5
Tablet 5 mg (as besylate)-160 mg	Oral	Exforge 5/160	NV	MP NP	C3307	28	5
Tablet 5 mg (as besylate)-320 mg	Oral	Exforge 5/320	NV	MP NP	C3307	28	5
Tablet 10 mg (as besylate)-160 mg	Oral	Exforge 10/160	NV	MP NP	C3307	28	5
Tablet 10 mg (as besylate)-320 mg	Oral	Exforge 10/320	NV	MP NP	C3307	28	5
Amlodipine with valsartan and hydrochlorothiazide	Tablet 5 mg (as besylate)-160 mg-12.5 mg	Oral	Exforge HCT 5/160/12.5	NV	MP NP	C3539	28	5
Tablet 5 mg (as besylate)-160 mg-25 mg	Oral	Exforge HCT 5/160/25	NV	MP NP	C3539	28	5
Tablet 10 mg (as besylate)-160 mg-12.5 mg	Oral	Exforge HCT 10/160/12.5	NV	MP NP	C3539	28	5
Tablet 10 mg (as besylate)-160 mg-25 mg	Oral	Exforge HCT 10/160/25	NV	MP NP	C3539	28	5
Tablet 10 mg (as besylate)-320 mg-25 mg	Oral	Exforge HCT 10/320/25	NV	MP NP	C3539	28	5
Amoxycillin	Tablet 1 g (as trihydrate)	Oral	Amoxycillin Sandoz	BG	MP NP	C1582	14	1
Maxamox	SZ	MP NP	C1582	14	1
Capsule 250 mg (as trihydrate)	Oral	Alphamox 250	AF	PDP	20	0
Amoxil	GK	PDP	20	0
Amoxycillin-GA	GM	PDP	20	0
Amoxycillin-PS	FZ	PDP	20	0
Amoxycillin Ranbaxy	RA	PDP	20	0
Amoxycillin Sandoz	SZ	PDP	20	0
APO-Amoxycillin	TX	PDP	20	0
Chem mart Amoxycillin	CH	PDP	20	0
Cilamox	QA	PDP	20	0
GenRx Amoxycillin	GX	PDP	20	0
Terry White Chemists Amoxycillin	TW	PDP	20	0
Alphamox 250	AF	MP NP MW	20	1
Amoxil	GK	MP NP MW	20	1
Amoxycillin-GA	GM	MP NP MW	20	1
Amoxycillin-PS	FZ	MP NP MW	20	1
Amoxycillin Ranbaxy	RA	MP NP MW	20	1
Amoxycillin Sandoz	SZ	MP NP MW	20	1
APO-Amoxycillin	TX	MP NP MW	20	1
Chem mart Amoxycillin	CH	MP NP MW	20	1
Cilamox	QA	MP NP MW	20	1
GenRx Amoxycillin	GX	MP NP MW	20	1
Terry White Chemists Amoxycillin	TW	MP NP MW	20	1
Capsule 500 mg (as trihydrate)	Oral	Alphamox 500	AF	PDP	20	0
Amoxil	GK	PDP	20	0
Amoxycillin-GA	GM	PDP	20	0
Amoxycillin generichealth 500	GQ	PDP	20	0
Amoxycillin-PS	FZ	PDP	20	0
Amoxycillin Ranbaxy	RA	PDP	20	0
Amoxycillin Sandoz	SZ	PDP	20	0
APO-Amoxycillin	TX	PDP	20	0
Chem mart Amoxycillin	CH	PDP	20	0
Cilamox	QA	PDP	20	0
GenRx Amoxycillin	GX	PDP	20	0
Terry White Chemists Amoxycillin	TW	PDP	20	0
Alphamox 500	AF	MP NP MW	20	1
Amoxil	GK	MP NP MW	20	1
Amoxycillin-GA	GM	MP NP MW	20	1
Amoxycillin generichealth 500	GQ	MP NP MW	20	1
Amoxycillin-PS	FZ	MP NP MW	20	1
Amoxycillin Ranbaxy	RA	MP NP MW	20	1
Amoxycillin Sandoz	SZ	MP NP MW	20	1
APO-Amoxycillin	TX	MP NP MW	20	1
Chem mart Amoxycillin	CH	MP NP MW	20	1
Cilamox	QA	MP NP MW	20	1
GenRx Amoxycillin	GX	MP NP MW	20	1
Terry White Chemists Amoxycillin	TW	MP NP MW	20	1
Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL	Oral	Amoxil	GK	PDP	1	0
Amoxil	GK	MP NP	1	1
Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL	Oral	Alphamox 125	AF	PDP	1	0
Amoxil	GK	PDP	1	0
Amoxycillin Sandoz	SZ	PDP	1	0
Bgramin	GM	PDP	1	0
Chem mart Amoxycillin	CH	PDP	1	0
GenRx Amoxycillin	GX	PDP	1	0
Ranmoxy	RA	PDP	1	0
Terry White Chemists Amoxycillin	TW	PDP	1	0
Alphamox 125	AF	MP NP	1	1
Amoxil	GK	MP NP	1	1
Amoxycillin Sandoz	SZ	MP NP	1	1
Bgramin	GM	MP NP	1	1
Chem mart Amoxycillin	CH	MP NP	1	1
GenRx Amoxycillin	GX	MP NP	1	1
Ranmoxy	RA	MP NP	1	1
Terry White Chemists Amoxycillin	TW	MP NP	1	1
Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL	Oral	Alphamox 250	AF	PDP	1	0
Amoxil Forte	GK	PDP	1	0
Amoxycillin Sandoz	SZ	PDP	1	0
Bgramin	GM	PDP	1	0
Chem mart Amoxycillin	CH	PDP	1	0
Cilamox	QA	PDP	1	0
GenRx Amoxycillin	GX	PDP	1	0
Ranmoxy	RA	PDP	1	0
Terry White Chemists Amoxycillin	TW	PDP	1	0
Alphamox 250	AF	MP NP	1	1
Amoxil Forte	GK	MP NP	1	1
Amoxycillin Sandoz	SZ	MP NP	1	1
Bgramin	GM	MP NP	1	1
Chem mart Amoxycillin	CH	MP NP	1	1
Cilamox	QA	MP NP	1	1
GenRx Amoxycillin	GX	MP NP	1	1
Ranmoxy	RA	MP NP	1	1
Terry White Chemists Amoxycillin	TW	MP NP	1	1
Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL	Oral	Maxamox	SZ	PDP	1	0
Maxamox	SZ	MP NP	1	1
Amoxycillin with Clavulanic Acid	Tablet containing 500 mg amoxycillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	Amoxycillin/ Clavulanic Acid 500/125 generichealth	GQ	PDP	C1836 C1837	10	0
APO-Amoxycillin/ Clavulanic Acid 500/125	TX	PDP	C1836 C1837	10	0
Augmentin Duo	GK	PDP	C1836 C1837	10	0
Clamoxyl Duo	AL	PDP	C1836 C1837	10	0
Curam Duo 500/125	SZ	PDP	C1836 C1837	10	0
GA-Amclav 500/125	GM	PDP	C1836 C1837	10	0
Moxiclav Duo 500/125	QA	PDP	C1836 C1837	10	0
Amoxycillin/ Clavulanic Acid 500/125 generichealth	GQ	MP NP MW	C1836 C1837	10	1
APO-Amoxycillin/ Clavulanic Acid 500/125	TX	MP NP MW	C1836 C1837	10	1
Augmentin Duo	GK	MP NP MW	C1836 C1837	10	1
Clamoxyl Duo	AL	MP NP MW	C1836 C1837	10	1
Curam Duo 500/125	SZ	MP NP MW	C1836 C1837	10	1
GA-Amclav 500/125	GM	MP NP MW	C1836 C1837	10	1
Moxiclav Duo 500/125	QA	MP NP MW	C1836 C1837	10	1
Tablet containing 875 mg amoxycillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	Amoxycillin/ Clavulanic Acid 875/125 generichealth	GQ	PDP	C1836 C1837	10	0

Augmentin Duo forte	GK	PDP	C1836 C1837	10	0
Chem mart Amoxycillin and Clavulanic Acid	CH	PDP	C1836 C1837	10	0
Clamoxyl Duo forte	AL	PDP	C1836 C1837	10	0
Clavycillin 875/125	CR	PDP	C1836 C1837	10	0
Curam Duo Forte 875/125	SZ	PDP	C1836 C1837	10	0
GA-Amclav Forte 875/125	GM	PDP	C1836 C1837	10	0
GenRx Amoxycillin and Clavulanic Acid	GX	PDP	C1836 C1837	10	0
Moxiclav Duo Forte 875/125	QA	PDP	C1836 C1837	10	0
Terry White Chemists Amoxycillin and Clavulanic Acid	TW	PDP	C1836 C1837	10	0
Amoxycillin/ Clavulanic Acid 875/125 generichealth	GQ	MP NP	C1836 C1837	10	1
Augmentin Duo forte	GK	MP NP	C1836 C1837	10	1
Chem mart Amoxycillin and Clavulanic Acid	CH	MP NP	C1836 C1837	10	1
Clamoxyl Duo forte	AL	MP NP	C1836 C1837	10	1
Clavycillin 875/125	CR	MP NP	C1836 C1837	10	1
Curam Duo Forte 875/125	SZ	MP NP	C1836 C1837	10	1
GA-Amclav Forte 875/125	GM	MP NP	C1836 C1837	10	1
GenRx Amoxycillin and Clavulanic Acid	GX	MP NP	C1836 C1837	10	1
Moxiclav Duo Forte 875/125	QA	MP NP	C1836 C1837	10	1
Terry White Chemists Amoxycillin and Clavulanic Acid	TW	MP NP	C1836 C1837	10	1
Powder for oral suspension containing 125 mg amoxycillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL	Oral	Augmentin	GK	PDP	C1836 C1837	1	0
Clamoxyl	AL	PDP	C1836 C1837	1	0
Curam	SZ	PDP	C1836 C1837	1	0
Augmentin	GK	MP NP	C1836 C1837	1	1
Clamoxyl	AL	MP NP	C1836 C1837	1	1
Curam	SZ	MP NP	C1836 C1837	1	1
Powder for oral suspension containing 400 mg amoxycillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL	Oral	Augmentin Duo 400	GK	PDP	C1836 C1837	1	0
Clamoxyl Duo 400	AL	PDP	C1836 C1837	1	0
Curam Duo	SZ	PDP	C1836 C1837	1	0
Augmentin Duo 400	GK	MP NP	C1836 C1837	1	1
Clamoxyl Duo 400	AL	MP NP	C1836 C1837	1	1
Curam Duo	SZ	MP NP	C1836 C1837	1	1
Amphotericin	Lozenge 10 mg	Oral	Fungilin	QA	PDP	20	0
MP NP	20	1
Ampicillin	Powder for injection 500 mg (as sodium)	Injection	Austrapen	LN	PDP	5	0
Ibimicyn	TS	PDP	5	0
Austrapen	LN	MP NP	5	1
Ibimicyn	TS	MP NP	5	1
Powder for injection 1 g (as sodium)	Injection	Aspen Ampicyn	AS	PDP	5	0
Austrapen	LN	PDP	5	0
Ibimicyn	TS	PDP	5	0
Aspen Ampicyn	AS	MP NP	5	1
Austrapen	LN	MP NP	5	1
Ibimicyn	TS	MP NP	5	1
Amylopectin, modified long chain	Sachets containing oral powder 60 g, 30 (Glycosade)	Oral	Glycosade	VF	MP NP	C3081	4	5
Anastrozole	Tablet 1 mg	Oral	Anastrol	QA	MP NP	C2213	30	5
Anastrozole-DRLA	RZ	MP NP	C2213	30	5
Anastrozole-GA	GM	MP NP	C2213	30	5
Anastrozole GH	GQ	MP NP	C2213	30	5
Anastrozole-PS	FZ	MP NP	C2213	30	5
Anastrozole RBX	RA	MP NP	C2213	30	5
Anastrozole Sandoz	SZ	MP NP	C2213	30	5
Anzole	WQ	MP NP	C2213	30	5
APO-Anastrozole	TX	MP NP	C2213	30	5
Arianna	AF	MP NP	C2213	30	5
Anastrozole Synthon	ZT	MP NP	C2213	30	5
Arimidex	AP	MP NP	C2213	30	5
Chem mart Anastrozole	CH	MP NP	C2213	30	5
Terry White Chemists Anastrozole	TW	MP NP	C2213	30	5
Apixaban	Tablet 2.5 mg	Oral	Eliquis	BQ	MP NP	C3957 C3991 C4043 C4044 C4046	P3957 P4043	20	0
MP NP	C3957 C3991 C4043 C4044 C4046	P3991 P4044	30	0
MP NP	C3957 C3991 C4043 C4044 C4046	P4046	60	0
Apomorphine	Injection containing apomorphine hydrochloride 20 mg in 2 mL	Injection	Apomine	HH	MP See Note 1	C1256 C3314	5	0	D
Injection containing apomorphine hydrochloride 50 mg in 5 mL	Injection	Apomine	HH	MP See Note 1	C1256 C3314	5	0	D
Solution for subcutaneous infusion containing apomorphine hydrochloride 50 mg in 10 mL pre-filled syringe	Injection	Apomine PFS	HH	MP See Note 1	C1256 C3314	5	0	D
Apraclonidine	Eye drops 5 mg (as hydrochloride) per mL, 10 mL	Application to the eye	Iopidine 0.5%	AQ	MP	C1374	1	2
Aprepitant	Pack containing 1 capsule 125 mg and 2 capsules 80 mg	Oral	Emend	MK	MP NP See Note 1	C3619 C3620 C3621	1	5
Arginine with carbohydrate	Sachets of oral powder 4 g containing 500 mg arginine, 30 (Arginine Amino Acid Supplement)	Oral	Arginine Amino Acid Supplement	VF	MP NP	C1458	4	5
Sachets of oral powder 4 g containing 2 g arginine, 30 (Arginine 2000 Amino Acid Supplement)	Oral	Arginine 2000 Amino Acid Supplement	VF	MP NP	C1458	4	5
Aripiprazole	Tablet 10 mg	Oral	Abilify	BQ	MP NP	C1589	30	5
Tablet 15 mg	Oral	Abilify	BQ	MP NP	C1589	30	5
Tablet 20 mg	Oral	Abilify	BQ	MP NP	C1589	30	5
Tablet 30 mg	Oral	Abilify	BQ	MP NP	C1589	30	5
Arsenic	Injection concentrate containing arsenic trioxide 10 mg in 10 mL	Injection	Phenasen	PL	MP	C3150 C3891	See Note 3	See Note 3	D
Artemether with lumefantrine	Tablet 20 mg-120 mg	Oral	Riamet	NV	MP	C3210	24	0
Tablet (dispersible) 20 mg-120 mg	Oral	Riamet 20mg/120mg Dispersible	NV	MP	C3551	18	0
Asenapine	Sublingual wafer 5 mg (as maleate)	Sublingual	Saphris	LU	MP NP	C1589 C3935 C3936	60	5
Sublingual wafer 10 mg (as maleate)	Sublingual	Saphris	LU	MP NP	C1589 C3935 C3936	60	5
Aspirin	Tablet 100 mg	Oral	Astrix	YN	MP NP	112	1
Mayne Pharma Aspirin	YT	MP NP	112	1
Spren 100	QA	MP NP	112	1
Tablet, dispersible, 300 mg	Oral	Solprin	RC	PDP	96	0
MP NP	96	1
Atazanavir	Capsule 100 mg (as sulfate)	Oral	Reyataz	BQ	MP See Note 1	C3586 C3587 C3588 C3589	120	5	D
Capsule 150 mg (as sulfate)	Oral	Reyataz	BQ	MP See Note 1	C3586 C3587 C3588 C3589	120	5	D
Capsule 200 mg (as sulfate)	Oral	Reyataz	BQ	MP See Note 1	C3586 C3587 C3588 C3589	120	5	D
Capsule 300 mg (as sulfate)	Oral	Reyataz	BQ	MP See Note 1	C3586 C3587 C3588 C3589	60	5	D
Atenolol	Tablet 50 mg	Oral	APO-Atenolol	TX	MP NP	30	5
Atenolol-GA	GN	MP NP	30	5
Atenolol generichealth	GQ	MP NP	30	5
Atenolol-PS	FZ	MP NP	30	5
Atenolol Sandoz	SZ	MP NP	30	5
Chem mart Atenolol	CH	MP NP	30	5
Noten	AF	MP NP	30	5
Tenormin	AP	MP NP	30	5
Tensig	QA	MP NP	30	5
Terry White Chemists Atenolol	TW	MP NP	30	5
Atomoxetine	Capsule 10 mg (as hydrochloride)	Oral	Strattera	LY	MP	C3025 C3026 C3027 C3028	56	5
Capsule 18 mg (as hydrochloride)	Oral	Strattera	LY	MP	C3025 C3026 C3027 C3028	56	5
Capsule 25 mg (as hydrochloride)	Oral	Strattera	LY	MP	C3025 C3026 C3027 C3028	56	5
Capsule 40 mg (as hydrochloride)	Oral	Strattera	LY	MP	C3025 C3026 C3027 C3028	56	5
Capsule 60 mg (as hydrochloride)	Oral	Strattera	LY	MP	C3025 C3026 C3027 C3028	56	5
Capsule 80 mg (as hydrochloride)	Oral	Strattera	LY	MP	C3025 C3026 C3027 C3028	28	5
Capsule 100 mg (as hydrochloride)	Oral	Strattera	LY	MP	C3025 C3026 C3027 C3028	28	5
Atorvastatin	Tablet 10 mg (as calcium)	Oral	APO-Atorvastatin	TX	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvachol	GM	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin GH	GQ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin Pfizer	FZ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin Sandoz	SZ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin SCP 10	RZ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Chem mart Atorvastatin	CH	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Lipitor	PF	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Lorstat 10	AF	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
STADA Atorvastatin	TD	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Terry White Chemists Atorvastatin	TW	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Torvastat 10	QA	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Trovas	RA	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
APO-Atorvastatin	TX	MP	C1540 C3047	P3047	30	11
Atorvachol	GM	MP	C1540 C3047	P3047	30	11
Atorvastatin GH	GQ	MP	C1540 C3047	P3047	30	11
Atorvastatin Pfizer	FZ	MP	C1540 C3047	P3047	30	11
Atorvastatin Sandoz	SZ	MP	C1540 C3047	P3047	30	11
Atorvastatin SCP 10	RZ	MP	C1540 C3047	P3047	30	11
Chem mart Atorvastatin	CH	MP	C1540 C3047	P3047	30	11
Lipitor	PF	MP	C1540 C3047	P3047	30	11
Lorstat 10	AF	MP	C1540 C3047	P3047	30	11
STADA Atorvastatin	TD	MP	C1540 C3047	P3047	30	11
Terry White Chemists Atorvastatin	TW	MP	C1540 C3047	P3047	30	11
Torvastat 10	QA	MP	C1540 C3047	P3047	30	11
Trovas	RA	MP	C1540 C3047	P3047	30	11
Tablet 20 mg (as calcium)	Oral	APO-Atorvastatin	TX	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvachol	GM	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin GH	GQ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin Pfizer	FZ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin Sandoz	SZ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin SCP 20	RZ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Chem mart Atorvastatin	CH	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Lipitor	PF	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Lorstat 20	AF	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
STADA Atorvastatin	TD	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Terry White Chemists Atorvastatin	TW	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Torvastat 20	QA	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Trovas	RA	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
APO-Atorvastatin	TX	MP	C1540 C3047	P3047	30	11
Atorvachol	GM	MP	C1540 C3047	P3047	30	11
Atorvastatin GH	GQ	MP	C1540 C3047	P3047	30	11
Atorvastatin Pfizer	FZ	MP	C1540 C3047	P3047	30	11
Atorvastatin Sandoz	SZ	MP	C1540 C3047	P3047	30	11
Atorvastatin SCP 20	RZ	MP	C1540 C3047	P3047	30	11
Chem mart Atorvastatin	CH	MP	C1540 C3047	P3047	30	11
Lipitor	PF	MP	C1540 C3047	P3047	30	11
Lorstat 20	AF	MP	C1540 C3047	P3047	30	11
STADA Atorvastatin	TD	MP	C1540 C3047	P3047	30	11
Terry White Chemists Atorvastatin	TW	MP	C1540 C3047	P3047	30	11
Torvastat 20	QA	MP	C1540 C3047	P3047	30	11
Trovas	RA	MP	C1540 C3047	P3047	30	11
Tablet 40 mg (as calcium)	Oral	APO-Atorvastatin	TX	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvachol	GM	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin GH	GQ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin Pfizer	FZ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin Sandoz	SZ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin SCP 40	RZ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Chem mart Atorvastatin	CH	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Lipitor	PF	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Lorstat 40	AF	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
STADA Atorvastatin	TD	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Terry White Chemists Atorvastatin	TW	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Torvastat 40	QA	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Trovas	RA	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
APO-Atorvastatin	TX	MP	C1540 C3047	P3047	30	11
Atorvachol	GM	MP	C1540 C3047	P3047	30	11
Atorvastatin GH	GQ	MP	C1540 C3047	P3047	30	11
Atorvastatin Pfizer	FZ	MP	C1540 C3047	P3047	30	11
Atorvastatin Sandoz	SZ	MP	C1540 C3047	P3047	30	11
Atorvastatin SCP 40	RZ	MP	C1540 C3047	P3047	30	11
Chem mart Atorvastatin	CH	MP	C1540 C3047	P3047	30	11
Lipitor	PF	MP	C1540 C3047	P3047	30	11
Lorstat 40	AF	MP	C1540 C3047	P3047	30	11
STADA Atorvastatin	TD	MP	C1540 C3047	P3047	30	11
Terry White Chemists Atorvastatin	TW	MP	C1540 C3047	P3047	30	11
Torvastat 40	QA	MP	C1540 C3047	P3047	30	11
Trovas	RA	MP	C1540 C3047	P3047	30	11
Tablet 80 mg (as calcium)	Oral	APO-Atorvastatin	TX	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvachol	GM	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin GH	GQ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin Pfizer	FZ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin Sandoz	SZ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Atorvastatin SCP 80	RZ	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Chem mart Atorvastatin	CH	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Lipitor	PF	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Lorstat 80	AF	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
STADA Atorvastatin	TD	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Terry White Chemists Atorvastatin	TW	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Torvastat 80	QA	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
Trovas	RA	MP	C1540 C3047	P1540	30	5
NP	C1540	30	5
APO-Atorvastatin	TX	MP	C1540 C3047	P3047	30	11
Atorvachol	GM	MP	C1540 C3047	P3047	30	11
Atorvastatin GH	GQ	MP	C1540 C3047	P3047	30	11
Atorvastatin Pfizer	FZ	MP	C1540 C3047	P3047	30	11
Atorvastatin Sandoz	SZ	MP	C1540 C3047	P3047	30	11
Atorvastatin SCP 80	RZ	MP	C1540 C3047	P3047	30	11
Chem mart Atorvastatin	CH	MP	C1540 C3047	P3047	30	11
Lipitor	PF	MP	C1540 C3047	P3047	30	11
Lorstat 80	AF	MP	C1540 C3047	P3047	30	11
STADA Atorvastatin	TD	MP	C1540 C3047	P3047	30	11
Terry White Chemists Atorvastatin	TW	MP	C1540 C3047	P3047	30	11
Torvastat 80	QA	MP	C1540 C3047	P3047	30	11
Trovas	RA	MP	C1540 C3047	P3047	30	11
Atovaquone	Oral suspension 750 mg per 5 mL, 210 mL	Oral	Wellvone	GK	MP NP	C1433	1	0
Atovaquone with proguanil	Tablet containing atovaquone 250 mg with proguanil hydrochloride 100 mg	Oral	Malarone	GK	MP NP	C3135	12	0
Atropine	Injection containing atropine sulfate 600 micrograms in 1 mL	Injection	Pfizer Australia Pty Ltd	PF	PDP	10	0
MP NP	10	1
Eye drops containing atropine sulfate 10 mg per mL, 15 mL	Application to the eye	Atropt	QA	MP NP	1	2
Auranofin	Tablet 3 mg	Oral	Ridaura	GH	MP NP	60	5
Capsule 3 mg	Oral	Ridaura	BZ	MP NP	60	5
Aurothiomalate	Injection containing sodium aurothiomalate 10 mg	Injection	Myocrisin	SW	MP NP	10	0
Injection containing sodium aurothiomalate 20 mg	Injection	Myocrisin	SW	MP NP	10	1
Injection containing sodium aurothiomalate 50 mg	Injection	Myocrisin	SW	MP NP	10	1
Azacitidine	Powder for injection 100 mg	Injection	Vidaza	CJ	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Azathioprine	Tablet 25 mg	Oral	Azathioprine Sandoz	SZ	MP NP	100	5
Imuran	AS	MP NP	100	5
Tablet 50 mg	Oral	Azamun	GM	MP NP	100	5
Azapin	QA	MP NP	100	5
Azathioprine-PS	FZ	MP NP	100	5
Azathioprine Sandoz	SZ	MP NP	100	5
GenRx Azathioprine	GX	MP NP	100	5
Imuran	AS	MP NP	100	5
Thioprine	AF	MP NP	100	5
Azithromycin	Tablet 500 mg (as dihydrate)	Oral	Azithromycin Sandoz	SZ	MP NP	C1405 C1838 C1839	P1838 P1839	2	0
Zithromax	PF	MP NP	C1405 C1838 C1839	P1838 P1839	2	0
Zitrocin	GM	MP NP	C1405 C1838 C1839	P1838 P1839	2	0
Azithromycin Sandoz	SZ	MP NP	C1405 C1838 C1839	P1405	2	2
Zithromax	PF	MP NP	C1405 C1838 C1839	P1405	2	2
Zitrocin	GM	MP NP	C1405 C1838 C1839	P1405	2	2
Tablet 600 mg (as dihydrate)	Oral	Zithromax	PF	MP See Note 1	C1299 C3317	16	5	PB
Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL	Oral	Zithromax	PF	MP NP	C1405	1	0
Baclofen	Tablet 10 mg	Oral	Chem mart Baclofen	CH	MP NP	100	5
Clofen 10	AF	MP NP	100	5
GenRx Baclofen	GX	MP NP	100	5
Lioresal 10	NV	MP NP	100	5
Stelax 10	QA	MP NP	100	5
Terry White Chemists Baclofen	TW	MP NP	100	5
Tablet 25 mg	Oral	Chem mart Baclofen	CH	MP NP	100	5
Clofen 25	AF	MP NP	100	5
GenRx Baclofen	GX	MP NP	100	5
Lioresal 25	NV	MP NP	100	5
Stelax 25	QA	MP NP	100	5
Terry White Chemists Baclofen	TW	MP NP	100	5
Intrathecal injection 10 mg in 5 mL	Injection	Lioresal Intrathecal	NV	MP See Note 1	C1637 C1638 C1639 C1640 C3318 C3319 C3320 C3321	10	0	PB
Balsalazide	Capsule containing balsalazide sodium 750 mg	Oral	Colazide	PK	MP NP	C1708 C1709	180	5
"BCG Immunotherapeutic" (Bacillus Calmette-Guérin/ Connaught strain)	Powder for intravesical administration containing 6.6 to 19.2 x 10 ⁸ CFU	Intravesical	ImmuCyst	SW	MP See Note 1	C1419	3	1
"BCG-Tice" (Bacillus Calmette-Guérin/Tice strain)	Vial containing powder for intravesical administration approximately 5 x 10 ⁸ CFU	Intravesical	OncoTICE	MK	MP See Note 1	C1290	3	1
Beclomethasone	Pressurised inhalation containing beclomethasone dipropionate 50 micrograms per dose, 200 doses (CFC-free formulation)	Inhalation by mouth	Qvar 50	IA	MP NP	1	5
Pressurised inhalation containing beclomethasone dipropionate 100 micrograms per dose, 200 doses (CFC-free formulation)	Inhalation by mouth	Qvar 100	IA	MP NP	1	5
Pressurised inhalation in breath actuated device containing beclomethasone dipropionate 50 micrograms per dose, 200 doses (CFC-free formulation)	Inhalation by mouth	Qvar 50 Autohaler	IA	MP NP	C1266	1	5
Pressurised inhalation in breath actuated device containing beclomethasone dipropionate 100 micrograms per dose, 200 doses (CFC-free formulation)	Inhalation by mouth	Qvar 100 Autohaler	IA	MP NP	C1266	1	5
Benzathine benzylpenicillin	Injection 900 mg in 2.3 mL single use pre-filled syringe	Injection	Bicillin L-A	PF	MP NP PDP	10	0
Benzhexol	Tablet containing benzhexol hydrochloride 2 mg	Oral	Artane	QA	MP NP	200	2
Tablet containing benzhexol hydrochloride 5 mg	Oral	Artane	QA	MP NP	200	1
Benztropine	Tablet containing benztropine mesylate 2 mg	Oral	Benztrop	PL	MP NP	60	2
Injection containing benztropine mesylate 2 mg in 2 mL	Injection	Cogentin	FK	MP NP PDP	5	0
Benzydamine	Mouth and throat rinse containing benzydamine hydrochloride 22.5 mg per 15 mL, 500 mL	Oral application	Difflam	IA	MP NP	C1669 C3634 C3635	P3635	1	0
PDP	C1669	1	0
MP NP	C1669 C3634 C3635	P1669	1	1
MP NP	C1669 C3634 C3635	P3634	1	3
Benzylpenicillin	Powder for injection 600 mg (as sodium)	Injection	BenPen	CS	PDP	10	0
MP NP MW	10	1
Powder for injection 3 g (as sodium)	Injection	BenPen	CS	MP NP PDP	10	0
Betamethasone	Injection containing betamethasone acetate 3 mg with betamethasone sodium phosphate 3.9 mg in 1 mL	Injection	Celestone Chronodose	MK	MP NP	C1020 C1102 C1146 C1189 C1191 C1192 C1197 C1237 C1465	5	0
Celestone Chronodose	MK	PDP	C1102 C1189 C1191	5	0
Cream 500 micrograms (as dipropionate) per g, 15 g	Application	Diprosone	MK	MP NP	C1422	1	1
Eleuphrat	FR	MP NP	C1422	1	1
Cream 200 micrograms (as valerate) per g, 100 g	Application	Antroquoril	FR	MP NP	C1422	2	0
Betnovate 1/5	QA	MP NP	C1422	2	0
Celestone-M	MK	MP NP	C1422	2	0
Cortival 1/5	FM	MP NP	C1422	2	0
Ointment 500 micrograms (as dipropionate) per g, 15 g	Application	Diprosone	MK	MP NP	C1422	1	1
Eleuphrat	FR	MP NP	C1422	1	1
Cream 500 micrograms (as valerate) per g, 15 g	Application	Betnovate 1/2	QA	MP NP	C1422	1	1
Cortival 1/2	FM	MP NP	C1422	1	1
Ointment 200 micrograms (as valerate) per g, 100 g	Application	Antroquoril	FR	MP NP	C1422	2	0
Celestone-M	MK	MP NP	C1422	2	0
Ointment 500 micrograms (as valerate) per g, 15 g	Application	Betnovate 1/2	QA	MP NP	C1422	1	1
Cortival 1/2	FM	MP NP	C1422	1	1
Betaxolol	Eye drops, suspension, 2.5 mg (as hydrochloride) per mL, 5 mL	Application to the eye	Betoptic S	AQ	MP AO	1	5
Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL	Application to the eye	Betoptic	AQ	MP AO	1	5
BetoQuin	IQ	MP AO	1	5
Bethanechol	Tablet containing bethanechol hydrochloride 10 mg	Oral	Uro-Carb	YN	MP NP	100	2
Bevacizumab	Solution for I.V. infusion 100 mg in 4 mL	Injection	Avastin	RO	MP	C3430 C3431 C3894 C3896	See Note 3	See Note 3	D
Solution for I.V. infusion 400 mg in 16 mL	Injection	Avastin	RO	MP	C3430 C3431 C3894 C3896	See Note 3	See Note 3	D
Bicalutamide	Tablet 50 mg	Oral	APO-Bicalutamide	TX	MP NP	C3674	28	5
Bicalutamide-GA	GM	MP NP	C3674	28	5
Bicalutamide Ranbaxy	RA	MP NP	C3674	28	5
Calutex	QA	MP NP	C3674	28	5
Cosamide	AF	MP NP	C3674	28	5
Cosudex	SZ	MP NP	C3674	28	5
Bimatoprost	Eye drops 300 micrograms per mL, 3 mL	Application to the eye	Lumigan	AG	MP AO	1	5
Bimatoprost with timolol	Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL	Application to the eye	Ganfort 0.3/5	AG	MP AO	C3426 C3427	1	5
Biperiden	Tablet containing biperiden hydrochloride 2 mg	Oral	Akineton	LM	MP NP	200	2
Bisacodyl	Tablet 5 mg	Oral	Bisalax	AS	MP NP	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643	P3643	200	0
Lax-Tab	AE	MP NP	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643	P3643	200	0
Bisalax	AS	MP NP	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643	P1025 P1122 P1221 P1254 P1263 P1268 P1400	200	2
Lax-Tab	AE	MP NP	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643	P1025 P1122 P1221 P1254 P1263 P1268 P1400	200	2
Bisalax	AS	MP NP	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643	P3642	200	3
Lax-Tab	AE	MP NP	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643	P3642	200	3
Tablets 5 mg, 200	Oral	Bisalax	AS	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	PB
Lax-Tab	AE	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	PB
Suppositories 10 mg, 10	Rectal	Dulcolax	BY	MP NP See Note 1	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643 See Note 2	P3643 See Note 2	3 See Note 2	0 See Note 2
Petrus Bisacodyl Suppositories	PP	MP NP See Note 1	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643 See Note 2	P3643 See Note 2	3 See Note 2	0 See Note 2
Dulcolax	BY	MP NP See Note 1	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643 See Note 2	P3642 See Note 2	3 See Note 2	3 See Note 2
Petrus Bisacodyl Suppositories	PP	MP NP See Note 1	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643 See Note 2	P3642 See Note 2	3 See Note 2	3 See Note 2
Dulcolax	BY	MP NP See Note 1	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643 See Note 2	P1025 P1122 P1221 P1254 P1263 P1268 P1400 See Note 2	3 See Note 2	5 See Note 2
Petrus Bisacodyl Suppositories	PP	MP NP See Note 1	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643 See Note 2	P1025 P1122 P1221 P1254 P1263 P1268 P1400 See Note 2	3 See Note 2	5 See Note 2
Suppositories 10 mg, 12	Rectal	Petrus Bisacodyl Suppositories	PP	MP NP See Note 1	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643 See Note 2	P3643 See Note 2	3 See Note 2	0 See Note 2
MP NP See Note 1	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643 See Note 2	P3642 See Note 2	3 See Note 2	3 See Note 2
MP NP See Note 1	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643 See Note 2	P1025 P1122 P1221 P1254 P1263 P1268 P1400 See Note 2	3 See Note 2	4 See Note 2
Enemas 10 mg in 5 mL, 25	Rectal	Bisalax	AS	MP NP See Note 1	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643 See Note 2	P3643 See Note 2	1 See Note 2	0 See Note 2
MP NP See Note 1	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643 See Note 2	P1025 P1122 P1221 P1254 P1263 P1268 P1400 See Note 2	1 See Note 2	2 See Note 2
Petrus Bisacodyl Suppositories	PP	NP	C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643 See Note 2	P3642 See Note 2	3 See Note 2	5 See Note 2
Bisoprolol	Tablet containing bisoprolol fumarate 2.5 mg	Oral	APO-Bisoprolol	TX	MP NP	C3234	28	5
Beprol 2.5	DO	MP NP	C3234	28	5
Bicard 2.5	QA	MP NP	C3234	28	5
Bicor	AL	MP NP	C3234	28	5
Biso 2.5	WQ	MP NP	C3234	28	5
Bisoprolol GH	GQ	MP NP	C3234	28	5
Bisoprolol Pfizer	FZ	MP NP	C3234	28	5
Bisoprolol Sandoz	SZ	MP NP	C3234	28	5
Bispro 2.5	AF	MP NP	C3234	28	5
Chem mart Bisoprolol	CH	MP NP	C3234	28	5
Terry White Chemists Bisoprolol	TW	MP NP	C3234	28	5
Tablet containing bisoprolol fumarate 5 mg	Oral	APO-Bisoprolol	TX	MP NP	C3234	28	5
Beprol 5	DO	MP NP	C3234	28	5
Bicard 5	QA	MP NP	C3234	28	5
Bicor	AL	MP NP	C3234	28	5
Biso 5	WQ	MP NP	C3234	28	5
Bisoprolol GH	GQ	MP NP	C3234	28	5
Bisoprolol Pfizer	FZ	MP NP	C3234	28	5
Bisoprolol Sandoz	SZ	MP NP	C3234	28	5
Bispro 5	AF	MP NP	C3234	28	5
Chem mart Bisoprolol	CH	MP NP	C3234	28	5
Terry White Chemists Bisoprolol	TW	MP NP	C3234	28	5
Tablet containing bisoprolol fumarate 10 mg	Oral	APO-Bisoprolol	TX	MP NP	C3234	28	5
Beprol 10	DO	MP NP	C3234	28	5
Bicard 10	QA	MP NP	C3234	28	5
Bicor	AL	MP NP	C3234	28	5
Biso 10	WQ	MP NP	C3234	28	5
Bisoprolol GH	GQ	MP NP	C3234	28	5
Bisoprolol Pfizer	FZ	MP NP	C3234	28	5
Bisoprolol Sandoz	SZ	MP NP	C3234	28	5
Bispro 10	AF	MP NP	C3234	28	5
Chem mart Bisoprolol	CH	MP NP	C3234	28	5
Terry White Chemists Bisoprolol	TW	MP NP	C3234	28	5
Bivalirudin	Powder for I.V. injection 250 mg (as trifluoroacetate)	Injection	Angiomax	XM	MP	C3075	1	0
Bleomycin	Powder for injection containing bleomycin sulfate 15,000 I.U.	Injection	Bleo 15K	WQ	MP	C1139 C1198	See Note 3	See Note 3	D
Hospira Pty Limited	HH	MP	C1139 C1198	See Note 3	See Note 3	D
Bortezomib	Powder for injection 3.5 mg	Injection	Velcade	JC	MP	C3762 C3763 C3764 C3765 C3766 C3767	See Note 3	See Note 3	D
Bosentan	Tablet 62.5 mg (as monohydrate)	Oral	Tracleer	AT	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Tablet 125 mg (as monohydrate)	Oral	Tracleer	AT	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Botulinum Toxin Type A Purified Neurotoxin Complex	Lyophilised powder for injection 100 units	Injection	Botox	AG	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Brimonidine	Eye drops containing brimonidine tartrate 1.5 mg per mL, 5 mL	Application to the eye	Alphagan P 1.5	AG	MP AO	1	5
Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL	Application to the eye	Alphagan	AG	MP AO	1	5
Enidin	PE	MP AO	1	5
Brimonidine with Timolol	Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL	Application to the eye	Combigan	AG	MP AO	C3426 C3427	1	5
Brinzolamide	Eye drops 10 mg per mL, 5 mL	Application to the eye	Azopt	AQ	MP AO	1	5
BrinzoQuin	IQ	MP AO	1	5
Brinzolamide with timolol	Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL	Application to the eye	Azarga	AQ	MP AO	C3426 C3427	1	5
Bromocriptine	Tablet 2.5 mg (as mesylate)	Oral	Kripton 2.5	AF	NP	C1289	30	0
MP	C1001 C1255 C1289 C1841 C1842 C1843 C1844	P1289	30	0
Parlodel	NV	NP	C1289	30	0
MP	C1001 C1255 C1289 C1841 C1842 C1843 C1844	P1289	30	0
Kripton 2.5	AF	MP	C1001 C1255 C1289 C1841 C1842 C1843 C1844	P1001 P1255 P1841 P1842 P1843 P1844	60	5
Parlodel	NV	MP	C1001 C1255 C1289 C1841 C1842 C1843 C1844	P1001 P1255 P1841 P1842 P1843 P1844	60	5
Capsule 5 mg (as mesylate)	Oral	Kripton 5	AF	MP	C1001 C1255 C1841 C1842 C1843 C1844	60	5
Capsule 10 mg (as mesylate)	Oral	Kripton 10	AF	MP	C1001 C1255 C1841 C1842 C1843 C1844	100	5
Budesonide	Nebuliser suspension 500 micrograms in 2 mL single dose units, 30	Inhalation	Pulmicort Respules	AP	MP NP	C1351	1	5
Nebuliser suspension 1 mg in 2 mL single dose units, 30	Inhalation	Pulmicort Respules	AP	MP NP	C1351	1	5
Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses	Inhalation by mouth	Pulmicort Turbuhaler	AP	MP NP	1	5
Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses	Inhalation by mouth	Pulmicort Turbuhaler	AP	MP NP	1	5
Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses	Inhalation by mouth	Pulmicort Turbuhaler	AP	MP NP	1	5
Budesonide with Eformoterol	Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses	Inhalation by mouth	Symbicort Turbuhaler 100/6	AP	MP NP	C1756 C1757 C2671 C2672 C2673	1	5
Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses	Inhalation by mouth	Symbicort Turbuhaler 200/6	AP	MP NP	C1756 C1757 C2671 C2672 C2673	1	5
Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses, 2	Inhalation by mouth	Symbicort Turbuhaler 400/12	AP	MP NP	C1756 C1757 C2680	1	5
Buprenorphine	Tablet (sublingual) 400 micrograms (as hydrochloride)	Sublingual	Subutex	RC	MP NP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	PB
Tablet (sublingual) 2 mg (as hydrochloride)	Sublingual	Subutex	RC	MP NP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	PB
Tablet (sublingual) 8 mg (as hydrochloride)	Sublingual	Subutex	RC	MP NP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	PB
Transdermal patch 5 mg	Transdermal	Norspan	MF	MP NP	C1062	2	0
Transdermal patch 10 mg	Transdermal	Norspan	MF	MP NP	C1062	2	0
Transdermal patch 20 mg	Transdermal	Norspan	MF	MP NP	C1062	2	0
Buprenorphine with naloxone	Tablet (sublingual) 2 mg (as hydrochloride)-0.5 mg (as hydrochloride)	Sublingual	Suboxone	RC	MP NP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Tablet (sublingual) 8 mg (as hydrochloride)-2 mg (as hydrochloride)	Sublingual	Suboxone	RC	MP NP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Film (soluble) 2 mg (as hydrochloride)-0.5 mg (as hydrochloride)	Sublingual	Suboxone Film 2/0.5	RC	MP NP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Film (soluble) 8 mg (as hydrochloride)-2 mg (as hydrochloride)	Sublingual	Suboxone Film 8/2	RC	MP NP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Bupropion	Tablet containing bupropion hydrochloride 150 mg (sustained release)	Oral	Prexaton	GM	MP NP	C2774 C2775 C2776	P2774 P2775	30	0
Zyban	GK	MP NP	C2774 C2775 C2776	P2774 P2775	30	0
Prexaton	GM	MP NP	C2774 C2775 C2776	P2776	90	0
Zyban	GK	MP NP	C2774 C2775 C2776	P2776	90	0
Busulfan	Tablet 2 mg	Oral	Myleran	AS	MP	100	0
Cabazitaxel	Concentrated injection 60 mg (as acetone solvate) in 1.5 mL, with diluent	Injection	Jevtana	SW	MP	C7000 C7001	See Note 3	See Note 3	D
Cabergoline	Tablet 500 micrograms	Oral	Dostan	GM	NP	C1289	2	0
MP	C1289 C2659 C2660 C2661 C2662	P1289	2	0
Dostinex	PF	NP	C1289	2	0
MP	C1289 C2659 C2660 C2661 C2662	P1289	2	0
Dostan	GM	MP	C1289 C2659 C2660 C2661 C2662	P2659 P2660 P2661 P2662	8	5
Dostinex	PF	MP	C1289 C2659 C2660 C2661 C2662	P2659 P2660 P2661 P2662	8	5
Tinexa	QA	MP	C2659 C2660 C2661 C2662	P2659 P2660 P2661 P2662	8	5
Tablet 1 mg	Oral	Bergoline 1	QA	MP NP	C1255	30	5
Cabaser	PF	MP NP	C1255	30	5
Cobasol	GM	MP NP	C1255	30	5
Tablet 2 mg	Oral	Bergoline 2	QA	MP NP	C1255	30	5
Cabaser	PF	MP NP	C1255	30	5
Cobasol	GM	MP NP	C1255	30	5
Calcipotriol	Cream 50 micrograms (as monohydrate) per g, 30 g	Application	Daivonex	LO	MP NP	C1066	1	1
Calcipotriol with betamethasone	Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g	Application	Daivobet	LO	MP NP	C3209	1	1
Gel containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g	Application	Daivobet 50/500 gel	LO	MP NP	C3827	1	1
Calcitriol	Capsule 0.25 microgram	Oral	Calciprox	GN	MP NP	C1165 C1166 C1167 C1467 C2636	100	3

Calcitriol-GA	GM	MP NP	C1165 C1166 C1167 C1467 C2636	100	3
Calcitriol-PS	FZ	MP NP	C1165 C1166 C1167 C1467 C2636	100	3
Calcitriol Sandoz	SZ	MP NP	C1165 C1166 C1167 C1467 C2636	100	3
GenRx Calcitriol	GX	MP NP	C1165 C1166 C1167 C1467 C2636	100	3
Kosteo	QA	MP NP	C1165 C1166 C1167 C1467 C2636	100	3
Rocaltrol	RO	MP NP	C1165 C1166 C1167 C1467 C2636	100	3
Sical	AF	MP NP	C1165 C1166 C1167 C1467 C2636	100	3
Calcium	Tablet, chewable, 500 mg (as carbonate)	Oral	Cal-Sup	IA	MP NP	C2212	240	1
Tablet 600 mg (as carbonate)	Oral	Calci-Tab 600	AE	MP NP	C2212	240	1
Candesartan	Tablet containing candesartan cilexetil 4 mg	Oral	Atacand	AP	MP NP	30	5
Tablet containing candesartan cilexetil 8 mg	Oral	Atacand	AP	MP NP	30	5
Tablet containing candesartan cilexetil 16 mg	Oral	Atacand	AP	MP NP	30	5
Tablet containing candesartan cilexetil 32 mg	Oral	Atacand	AP	MP NP	30	5
Candesartan with Hydrochlorothiazide	Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg	Oral	Atacand Plus 16/12.5	AP	MP NP	C3307	30	5
Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg	Oral	Atacand Plus 32/12.5	AP	MP NP	C3307	30	5
Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg	Oral	Atacand Plus 32/25	AP	MP NP	C3307	30	5
Capecitabine	Tablet 150 mg	Oral	Xeloda	RO	MP	C1522 C1614 C1738 C1739 C3509 C3942	60	2
Tablet 500 mg	Oral	Xeloda	RO	MP	C1522 C1614 C1738 C1739 C3509 C3942	120	2
Captopril	Tablet 12.5 mg	Oral	Captopril Sandoz	SZ	MP NP	90	5
GenRx Captopril	GX	MP NP	90	5
Zedace	AF	MP NP	90	5
Tablet 25 mg	Oral	Capoten	QA	MP NP	90	5
Captopril Sandoz	SZ	MP NP	90	5
GenRx Captopril	GX	MP NP	90	5
Zedace	AF	MP NP	90	5
Tablet 50 mg	Oral	Capoten	QA	MP NP	90	5
Captopril Sandoz	SZ	MP NP	90	5
GenRx Captopril	GX	MP NP	90	5
Zedace	AF	MP NP	90	5
Oral solution 5 mg per mL, 95 mL	Oral	Capoten	QA	MP NP	C1998	1	5
Carbamazepine	Tablet 100 mg	Oral	Carbamazepine Sandoz	SZ	PDP	200	0
Tegretol 100	NV	PDP	200	0
Carbamazepine Sandoz	SZ	MP NP	200	2
Tegretol 100	NV	MP NP	200	2
Tablet 200 mg	Oral	Carbamazepine Sandoz	SZ	PDP	200	0
Tegretol 200	NV	PDP	200	0
Teril	AF	PDP	200	0
Carbamazepine Sandoz	SZ	MP NP	200	2
Tegretol 200	NV	MP NP	200	2
Teril	AF	MP NP	200	2
Tablet 200 mg (controlled release)	Oral	Tegretol CR 200	NV	PDP	200	0
MP NP	200	2
Tablet 400 mg (controlled release)	Oral	Tegretol CR 400	NV	PDP	200	0
MP NP	200	2
Oral suspension 100 mg per 5 mL, 300 mL	Oral	Tegretol Liquid	NV	PDP	1	0
MP NP	1	5
Carbimazole	Tablet 5 mg	Oral	Neo-Mercazole	LM	MP NP	200	2
Carbohydrate, fat, vitamins, minerals and trace elements	Oral powder 400 g (Energivit)	Oral	Energivit	SB	MP NP	C1276	8	5
Carbomer	Eye gel 2 mg per g, 10 g	Application to the eye	GelTears	BU	MP	C1362 C3036	P1362	1	5
NP AO	C1362	1	5
PAA	IQ	MP	C1362 C3036	P1362	1	5
NP AO	C1362	1	5
Viscotears	AQ	MP	C1362 C3036	P1362	1	5
NP AO	C1362	1	5
GelTears	BU	MP	C1362 C3036	P3036	1	11
PAA	IQ	MP	C1362 C3036	P3036	1	11
Viscotears	AQ	MP	C1362 C3036	P3036	1	11
Eye gel 2 mg per g, single dose units 0.6 mL, 30	Application to the eye	Viscotears Gel PF	AQ	MP NP	C1359	3	5
AO	C2802	3	5
Carbomer 974	Ocular lubricating gel 3 mg per g, single dose units 0.5 g, 30	Application to the eye	Poly Gel	AQ	MP NP	C1359	3	5
AO	C2802	3	5
Carboplatin	Solution for I.V. injection 50 mg in 5 mL	Injection	Carboplatin Ebewe	SZ	MP	See Note 3	See Note 3	D
Hospira Pty Limited	HH	MP	See Note 3	See Note 3	D
Solution for I.V. injection 150 mg in 15 mL	Injection	Carboplatin Ebewe	SZ	MP	See Note 3	See Note 3	D
Hospira Pty Limited	HH	MP	See Note 3	See Note 3	D
Pfizer Australia Pty Ltd	PF	MP	See Note 3	See Note 3	D
Solution for I.V. injection 450 mg in 45 mL	Injection	Carboplatin Ebewe	SZ	MP	See Note 3	See Note 3	D
Carboplatin Kabi	PK	MP	See Note 3	See Note 3	D
Hospira Pty Limited	HH	MP	See Note 3	See Note 3	D
Pfizer Australia Pty Ltd	PF	MP	See Note 3	See Note 3	D
Carmellose	Eye drops containing carmellose sodium 5 mg per mL, 15 mL	Application to the eye	Refresh Tears Plus	AG	MP	C1362 C3036	P1362	1	5
NP AO	C1362	1	5
MP	C1362 C3036	P3036	1	11
Eye drops containing carmellose sodium 10 mg per mL, 15 mL	Application to the eye	Refresh Liquigel	AG	MP	C1362 C3036	P1362	1	5
NP AO	C1362	1	5
MP	C1362 C3036	P3036	1	11
Eye drops containing carmellose sodium 2.5 mg per mL, single dose units 0.6 mL, 24	Application to the eye	TheraTears	CX	MP NP	C1359	4	5
AO	C2802	4	5
Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30	Application to the eye	Cellufresh	AG	MP NP	C1359	3	5
AO	C2802	3	5
Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30	Application to the eye	Celluvisc	AG	MP NP	C1359	3	5
AO	C2802	3	5
Ocular lubricating gel containing carmellose sodium 10 mg per mL, single dose units 0.6 mL, 28	Application to the eye	TheraTears	CX	MP NP	C1359	3	5
AO	C2802	3	5
Mouth spray containing carmellose sodium 10 mg per mL, 25 mL	Oral application	Aquae	VT	MP NP	C3636 C3637	P3637	1	0
MP NP	C3636 C3637	P3636	1	3
Mouth spray containing carmellose sodium 10 mg per mL, 100 mL	Oral application	Aquae	VT	MP NP	C3636 C3637	P3637	1	0
MP NP	C3636 C3637	P3636	1	3
Carmellose with glycerin	Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL	Application to the eye	Optive	AG	MP	C1362 C3036	P1362	1	3
NP AO	C1362	1	3
MP	C1362 C3036	P3036	1	7
Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, single dose units 0.4 mL, 30	Application to the eye	Optive	AG	AO	C2802	3	5
MP NP	C1359	3	5
Carmustine	Implants 7.7 mg, 8	Implantation	Gliadel	OA	MP	C2462	1	0
Carvedilol	Tablet 3.125 mg	Oral	APO-Carvedilol	TX	MP NP	C1735 C3234	30	0
Chem mart Carvedilol 3.125 mg	CH	MP NP	C1735 C3234	30	0
Dilatrend 3.125	RO	MP NP	C1735 C3234	30	0
GenRx Carvedilol	GX	MP NP	C1735 C3234	30	0
GN-Carvedilol	GM	MP NP	C1735 C3234	30	0
Terry White Chemists Carvedilol 3.125 mg	TW	MP NP	C1735 C3234	30	0
Vedilol 3.125	QA	MP NP	C1735 C3234	30	0
Volirop 3.125	DO	MP NP	C1735 C3234	30	0
Tablet 6.25 mg	Oral	APO-Carvedilol	TX	MP NP	C1735 C3234	60	5
Carvedilol generichealth	GQ	MP NP	C1735 C3234	60	5
Carvedilol Sandoz	SZ	MP NP	C1735 C3234	60	5
Chem mart Carvedilol 6.25 mg	CH	MP NP	C1735 C3234	60	5
Dicarz	AF	MP NP	C1735 C3234	60	5
Dilatrend 6.25	RO	MP NP	C1735 C3234	60	5
GenRx Carvedilol	GX	MP NP	C1735 C3234	60	5
GN-Carvedilol	GM	MP NP	C1735 C3234	60	5
Terry White Chemists Carvedilol 6.25 mg	TW	MP NP	C1735 C3234	60	5
Vedilol 6.25	QA	MP NP	C1735 C3234	60	5
Volirop 6.25	DO	MP NP	C1735 C3234	60	5
Tablet 12.5 mg	Oral	APO-Carvedilol	TX	MP NP	C1735 C3234	60	5
Carvedilol generichealth	GQ	MP NP	C1735 C3234	60	5
Carvedilol Sandoz	SZ	MP NP	C1735 C3234	60	5
Chem mart Carvedilol 12.5 mg	CH	MP NP	C1735 C3234	60	5
Dicarz	AF	MP NP	C1735 C3234	60	5
Dilatrend 12.5	RO	MP NP	C1735 C3234	60	5
GenRx Carvedilol	GX	MP NP	C1735 C3234	60	5
GN-Carvedilol	GM	MP NP	C1735 C3234	60	5
Terry White Chemists Carvedilol 12.5 mg	TW	MP NP	C1735 C3234	60	5
Vedilol 12.5	QA	MP NP	C1735 C3234	60	5
Volirop 12.5	DO	MP NP	C1735 C3234	60	5
Tablet 25 mg	Oral	APO-Carvedilol	TX	MP NP	C1735 C3234	60	5
Carvedilol generichealth	GQ	MP NP	C1735 C3234	60	5
Carvedilol Sandoz	SZ	MP NP	C1735 C3234	60	5
Chem mart Carvedilol 25 mg	CH	MP NP	C1735 C3234	60	5
Dicarz	AF	MP NP	C1735 C3234	60	5
Dilatrend 25	RO	MP NP	C1735 C3234	60	5
GenRx Carvedilol	GX	MP NP	C1735 C3234	60	5
GN-Carvedilol	GM	MP NP	C1735 C3234	60	5
Terry White Chemists Carvedilol 25 mg	TW	MP NP	C1735 C3234	60	5
Vedilol 25	QA	MP NP	C1735 C3234	60	5
Volirop 25	DO	MP NP	C1735 C3234	60	5
Cefaclor	Tablet (sustained release) 375 mg (as monohydrate)	Oral	Ceclor CD	AS	PDP	10	0
Cefaclor-GA	GN	PDP	10	0
Cefaclor GH	GQ	PDP	10	0
Chem mart Cefaclor CD	CH	PDP	10	0
GenRx Cefaclor CD	GX	PDP	10	0
Karlor CD	LN	PDP	10	0
Keflor CD	AF	PDP	10	0
Ozcef	RA	PDP	10	0
Terry White Chemists Cefaclor CD	TW	PDP	10	0
Ceclor CD	AS	MP	10	1
Cefaclor-GA	GN	MP	10	1
Cefaclor GH	GQ	MP	10	1
Chem mart Cefaclor CD	CH	MP	10	1
GenRx Cefaclor CD	GX	MP	10	1
Karlor CD	LN	MP	10	1
Keflor CD	AF	MP	10	1
Ozcef	RA	MP	10	1
Terry White Chemists Cefaclor CD	TW	MP	10	1
Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL	Oral	Aclor 125	QA	PDP	1	0
Ceclor	AS	PDP	1	0
Cefaclor Sandoz	SZ	PDP	1	0
Chem mart Cefaclor	CH	PDP	1	0
GenRx Cefaclor	GX	PDP	1	0
Keflor	AF	PDP	1	0
Ozcef	RA	PDP	1	0
Terry White Chemists Cefaclor	TW	PDP	1	0
Aclor 125	QA	MP	1	1
Ceclor	AS	MP	1	1
Cefaclor Sandoz	SZ	MP	1	1
Chem mart Cefaclor	CH	MP	1	1
GenRx Cefaclor	GX	MP	1	1
Keflor	AF	MP	1	1
Ozcef	RA	MP	1	1
Terry White Chemists Cefaclor	TW	MP	1	1
Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL	Oral	Aclor 250	QA	PDP	1	0
Ceclor	AS	PDP	1	0
Cefaclor Sandoz	SZ	PDP	1	0
Chem mart Cefaclor	CH	PDP	1	0
GenRx Cefaclor	GX	PDP	1	0
Keflor	AF	PDP	1	0
Ozcef	RA	PDP	1	0
Terry White Chemists Cefaclor	TW	PDP	1	0
Aclor 250	QA	MP	1	1
Ceclor	AS	MP	1	1
Cefaclor Sandoz	SZ	MP	1	1
Chem mart Cefaclor	CH	MP	1	1
GenRx Cefaclor	GX	MP	1	1
Keflor	AF	MP	1	1
Ozcef	RA	MP	1	1
Terry White Chemists Cefaclor	TW	MP	1	1
Cefalotin	Powder for injection 1 g (as sodium)	Injection	Cefalotin Sandoz	SZ	PDP	10	0
Hospira Pty Limited	HH	PDP	10	0
Keflin Neutral	AS	PDP	10	0
Cefalotin Sandoz	SZ	MP NP	10	1
Hospira Pty Limited	HH	MP NP	10	1
Keflin Neutral	AS	MP NP	10	1
Cefepime	Powder for injection 1 g (as hydrochloride)	Injection	Cefepime Sandoz	SZ	MP NP	C1427	10	0
DBL Cefepime	HH	MP NP	C1427	10	0
Omegapharm Pty Ltd	OE	MP NP	C1427	10	0
Powder for injection 2 g (as hydrochloride)	Injection	Cefepime Sandoz	SZ	MP NP	C1427	10	0
DBL Cefepime	HH	MP NP	C1427	10	0
Maxipime	BQ	MP NP	C1427	10	0
Omegapharm Pty Ltd	OE	MP NP	C1427	10	0
Cefotaxime	Powder for injection 1 g (as sodium)	Injection	Cefotaxime Sandoz	SZ	MP NP	C1169 C1846 C1847	10	0
PDP	C1169	10	0
Hospira Pty Limited	HH	MP NP	C1169 C1846 C1847	10	0
PDP	C1169	10	0
Powder for injection 2 g (as sodium)	Injection	Cefotaxime Sandoz	SZ	MP NP	C1169 C1846 C1847	10	0
PDP	C1169	10	0
Hospira Pty Limited	HH	MP NP	C1169 C1846 C1847	10	0
PDP	C1169	10	0
Ceftriaxone	Powder for injection 500 mg (as sodium)	Injection	Ceftriaxone-AFT	AE	MP NP	C1143 C1169 C1846 C1847	P1143	1	0
Ceftriaxone ICP	PP	MP NP	C1143 C1169 C1846 C1847	P1143	1	0
Ceftriaxone-AFT	AE	MP NP	C1143 C1169 C1846 C1847	P1169 P1846 P1847	5	0
Ceftriaxone ICP	PP	MP NP	C1143 C1169 C1846 C1847	P1169 P1846 P1847	5	0
Powder for injection 1 g (as sodium)	Injection	Ceftriaxone-AFT	AE	MP NP	C1169 C1846 C1847	5	0
Ceftriaxone ICP	PP	MP NP	C1169 C1846 C1847	5	0
Ceftriaxone Sandoz	SZ	MP NP	C1169 C1846 C1847	5	0
DBL Ceftriaxone	HH	MP NP	C1169 C1846 C1847	5	0
Max Pharma Ceftriaxone	GQ	MP NP	C1169 C1846 C1847	5	0
Rocephin	RO	MP NP	C1169 C1846 C1847	5	0
Powder for injection 2 g (as sodium)	Injection	Ceftriaxone-AFT	AE	MP NP	C1169 C1846 C1847	5	0
Ceftriaxone ICP	PP	MP NP	C1169 C1846 C1847	5	0
Ceftriaxone Sandoz	SZ	MP NP	C1169 C1846 C1847	5	0
DBL Ceftriaxone	HH	MP NP	C1169 C1846 C1847	5	0
Rocephin	RO	MP NP	C1169 C1846 C1847	5	0
Cefuroxime	Tablet 250 mg (as axetil)	Oral	Zinnat	GK	PDP	14	0
MP	14	1
Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL	Oral	Zinnat	GK	PDP	1	0
MP	1	1
Celecoxib	Capsule 100 mg	Oral	Celebrex	PF	MP NP	C1547 C1848	60	3
Capsule 200 mg	Oral	Celebrex	PF	MP NP	C1547 C1848	30	3
Cephalexin	Capsule 250 mg (anhydrous)	Oral	Cefalexin Sandoz	SZ	PDP	20	0
Cephalexin generichealth	GQ	PDP	20	0
Cephalexin-PS	FZ	PDP	20	0
Cephatrust 250	MI	PDP	20	0
Chem mart Cephalexin	CH	PDP	20	0
Cilex	GM	PDP	20	0
GenRx Cephalexin	GX	PDP	20	0
Ialex	LN	PDP	20	0
Ibilex 250	AF	PDP	20	0
Keflex	AS	PDP	20	0
Pharmacor Cephalexin 250	CR	PDP	20	0
Rancef	RA	PDP	20	0
Terry White Chemists Cephalexin	TW	PDP	20	0
Cefalexin Sandoz	SZ	MP NP MW	20	1
Cephalexin generichealth	GQ	MP NP MW	20	1
Cephalexin-PS	FZ	MP NP MW	20	1
Cephatrust 250	MI	MP NP MW	20	1
Chem mart Cephalexin	CH	MP NP MW	20	1
Cilex	GM	MP NP MW	20	1
GenRx Cephalexin	GX	MP NP MW	20	1
Ialex	LN	MP NP MW	20	1
Ibilex 250	AF	MP NP MW	20	1
Keflex	AS	MP NP MW	20	1
Pharmacor Cephalexin 250	CR	MP NP MW	20	1
Rancef	RA	MP NP MW	20	1
Terry White Chemists Cephalexin	TW	MP NP MW	20	1
Capsule 500 mg (anhydrous)	Oral	Cefalexin Sandoz	SZ	PDP	20	0
Cephalexin generichealth	GQ	PDP	20	0
Cephalexin-PS	FZ	PDP	20	0
Cephatrust 500	MI	PDP	20	0
Chem mart Cephalexin	CH	PDP	20	0
Cilex	GM	PDP	20	0
GenRx Cephalexin	GX	PDP	20	0
Ialex	LN	PDP	20	0
Ibilex 500	AF	PDP	20	0
Keflex	AS	PDP	20	0
Pharmacor Cephalexin 500	CR	PDP	20	0
Rancef	RA	PDP	20	0
Terry White Chemists Cephalexin	TW	PDP	20	0
Cefalexin Sandoz	SZ	MP NP MW	20	1
Cephalexin generichealth	GQ	MP NP MW	20	1
Cephalexin-PS	FZ	MP NP MW	20	1
Cephatrust 500	MI	MP NP MW	20	1
Chem mart Cephalexin	CH	MP NP MW	20	1
Cilex	GM	MP NP MW	20	1
GenRx Cephalexin	GX	MP NP MW	20	1
Ialex	LN	MP NP MW	20	1
Ibilex 500	AF	MP NP MW	20	1
Keflex	AS	MP NP MW	20	1
Pharmacor Cephalexin 500	CR	MP NP MW	20	1
Rancef	RA	MP NP MW	20	1
Terry White Chemists Cephalexin	TW	MP NP MW	20	1
Granules for oral suspension 125 mg per 5 mL, 100 mL	Oral	APO-Cephalexin	TX	PDP	1	0
Cefalexin Sandoz	SZ	PDP	1	0
Chem mart Cephalexin	CH	PDP	1	0
Cilex	GM	PDP	1	0
GenRx Cephalexin	GX	PDP	1	0
Ialex	LN	PDP	1	0
Ibilex 125	AF	PDP	1	0
Keflex	AS	PDP	1	0
Terry White Chemists Cephalexin	TW	PDP	1	0
APO-Cephalexin	TX	MP NP	1	1
Cefalexin Sandoz	SZ	MP NP	1	1
Chem mart Cephalexin	CH	MP NP	1	1
Cilex	GM	MP NP	1	1
GenRx Cephalexin	GX	MP NP	1	1
Ialex	LN	MP NP	1	1
Ibilex 125	AF	MP NP	1	1
Keflex	AS	MP NP	1	1
Terry White Chemists Cephalexin	TW	MP NP	1	1
Granules for oral suspension 250 mg per 5 mL, 100 mL	Oral	APO-Cephalexin	TX	PDP	1	0
Cefalexin Sandoz	SZ	PDP	1	0
Chem mart Cephalexin	CH	PDP	1	0
Cilex	GM	PDP	1	0
GenRx Cephalexin	GX	PDP	1	0
Ialex	LN	PDP	1	0
Ibilex 250	AF	PDP	1	0
Keflex	AS	PDP	1	0
Terry White Chemists Cephalexin	TW	PDP	1	0
APO-Cephalexin	TX	MP NP	1	1
Cefalexin Sandoz	SZ	MP NP	1	1
Chem mart Cephalexin	CH	MP NP	1	1
Cilex	GM	MP NP	1	1
GenRx Cephalexin	GX	MP NP	1	1
Ialex	LN	MP NP	1	1
Ibilex 250	AF	MP NP	1	1
Keflex	AS	MP NP	1	1
Terry White Chemists Cephalexin	TW	MP NP	1	1
Cephazolin	Powder for injection 500 mg (as sodium)	Injection	Cefazolin-AFT	AE	MP NP	C1169 C1846 C1847 C3132	10	0
Hospira Pty Limited	HH	MP NP	C1169 C1846 C1847 C3132	10	0
Powder for injection 1 g (as sodium)	Injection	Cefazolin-AFT	AE	MP NP	C1169 C1846 C1847 C3132	10	0
Cefazolin Sandoz	SZ	MP NP	C1169 C1846 C1847 C3132	10	0
Cephazolin Alphapharm	AF	MP NP	C1169 C1846 C1847 C3132	10	0
Hospira Pty Limited	HH	MP NP	C1169 C1846 C1847 C3132	10	0
Kefzol	AS	MP NP	C1169 C1846 C1847 C3132	10	0
Powder for injection 2 g (as sodium)	Injection	Cefazolin Sandoz	SZ	MP NP	C1169 C1846 C1847 C3132	10	0
Cephazolin Alphapharm	AF	MP NP	C1169 C1846 C1847 C3132	10	0
Certolizumab pegol	Injection 200 mg in 1 mL single use pre-filled syringe	Injection	Cimzia	UC	MP	C3714 C3768 C3769	2	5
Cetrorelix	Powder for injection 250 micrograms (as acetate) with diluent	Injection	Cetrotide	SG	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Cetuximab	Solution for I.V. infusion 100 mg in 20 mL	Injection	Erbitux	SG	MP	C2713 C2714 C2715 C3843 C3844 C3903 C3904 C3919 C3920 C3921	See Note 3	See Note 3	See Note 3	D
Solution for I.V. infusion 500 mg in 100 mL	Injection	Erbitux	SG	MP	C2713 C2714 C2715 C3843 C3844 C3903 C3904 C3919 C3920 C3921	See Note 3	See Note 3	See Note 3	D
Chlorambucil	Tablet 2 mg	Oral	Leukeran	AS	MP	100	2
Chloramphenicol	Ear drops (aqueous) 5 mg per mL, 5 mL	Application to the ear	Chloromycetin	PF	MP NP	1	2
Eye drops 5 mg per mL, 10 mL	Application to the eye	Chloromycetin	PF	PDP	1	0
Chlorsig	QA	PDP	1	0
Chloromycetin	PF	AO MP NP MW	1	2
Chlorsig	QA	AO MP NP MW	1	2
Eye ointment 10 mg per g, 4 g	Application to the eye	Chloromycetin	PF	AO MP NP MW	1	0
Chlorsig	QA	AO MP NP MW	1	0
Chlorpromazine	Tablet containing chlorpromazine hydrochloride 10 mg	Oral	Largactil	SW	MP NP	100	5
Tablet containing chlorpromazine hydrochloride 25 mg	Oral	Largactil	SW	MP NP	100	5
Tablet containing chlorpromazine hydrochloride 100 mg	Oral	Largactil	SW	MP NP	100	5
Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL	Oral	Largactil	SW	MP NP	1	5
Injection containing chlorpromazine hydrochloride 50 mg in 2 mL	Injection	Largactil	SW	MP NP	10	0
Chlorthalidone	Tablet 25 mg	Oral	Hygroton 25	LM	MP NP	100	1
Cholestyramine	Sachets containing 4.7 g oral powder (equivalent to 4 g cholestyramine), 50	Oral	Questran Lite	QA	MP NP	2	5
Questran Lite	QA	MP	P3035	2	11
Choriogonadotropin alfa	Solution for injection 250 micrograms in 0.5 mL pre-filled syringe	Injection	Ovidrel	SG	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Solution for injection 250 micrograms in 0.5 mL pre-filled pen	Injection	Ovidrel	SG	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Chorionic Gonadotrophin	Injection set containing 3 ampoules powder for injection 1,500 units and 3 ampoules solvent 1 mL	Injection	Pregnyl	MK	MP See Note 1	C1116 C1117 C1118 C1120 C1878 See Note 2	See Note 2	1 See Note 2	5 See Note 2
Powder for injection 5,000 units with solvent	Injection	Pregnyl	MK	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	PB
Ciclesonide	Pressurised inhalation 80 micrograms per dose, 120 doses (CFC-free formulation)	Inhalation by mouth	Alvesco 80	NQ	MP NP	1	5
Pressurised inhalation 160 micrograms per dose, 120 doses (CFC-free formulation)	Inhalation by mouth	Alvesco 160	NQ	MP NP	1	5
Cidofovir	Solution for I.V. infusion 375 mg (anhydrous) in 5 mL single use vial	Injection	Vistide	GI	MP See Note 1	C1610 C3322	4	3	D
Cimetidine	Tablet 400 mg	Oral	Magicul 400	AF	MP NP	60	5
Tablet 800 mg	Oral	Magicul 800	AF	MP NP	30	5
Cinacalcet	Tablet 30 mg (as hydrochloride)	Oral	Sensipar	AN	MP	C3672 C3673	P3672 P3673	28	5
NP	C3672 C3673	28	5
MP See Note 1	C2893 C2894 C3323 C3324	56	5	C
Tablet 60 mg (as hydrochloride)	Oral	Sensipar	AN	MP	C3672 C3673	P3672 P3673	28	5
NP	C3672 C3673	28	5
MP See Note 1	C2893 C2894 C3323 C3324	56	5	C
Tablet 90 mg (as hydrochloride)	Oral	Sensipar	AN	MP	C3672 C3673	P3672 P3673	28	5
NP	C3672 C3673	28	5
MP See Note 1	C2893 C2894 C3323 C3324	56	5	C
Ciprofloxacin	Tablet 250 mg (as hydrochloride)	Oral	C-Flox 250	AL	MP NP	C1143 C1431 C1432 C1572 C1573	14	0
Cifran	RA	MP NP	C1143 C1431 C1432 C1572 C1573	14	0
Ciprofloxacin-DRLA	RZ	MP NP	C1143 C1431 C1432 C1572 C1573	14	0
Ciprofloxacin Sandoz	SZ	MP NP	C1143 C1431 C1432 C1572 C1573	14	0
Ciprol 250	QA	MP NP	C1143 C1431 C1432 C1572 C1573	14	0
Ciproxin 250	BN	MP NP	C1143 C1431 C1432 C1572 C1573	14	0
GenRx Ciprofloxacin	GX	MP NP	C1143 C1431 C1432 C1572 C1573	14	0
Profloxin	HX	MP NP	C1143 C1431 C1432 C1572 C1573	14	0
Tablet 500 mg (as hydrochloride)	Oral	C-Flox 500	AL	MP NP	C1431 C1432 C1572 C1573	14	0
Cifran	RA	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprofloxacin 500	CR	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprofloxacin-BW	GQ	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprofloxacin-DRLA	RZ	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprofloxacin-GA	GM	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprofloxacin-PS	FZ	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprofloxacin Sandoz	SZ	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprol 500	QA	MP NP	C1431 C1432 C1572 C1573	14	0
Ciproxin 500	BN	MP NP	C1431 C1432 C1572 C1573	14	0
GenRx Ciprofloxacin	GX	MP NP	C1431 C1432 C1572 C1573	14	0
Loxip 500	DO	MP NP	C1431 C1432 C1572 C1573	14	0
Tablet 750 mg (as hydrochloride)	Oral	C-Flox 750	AL	MP NP	C1431 C1432 C1572 C1573	14	0
Cifran	RA	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprofloxacin 750	CR	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprofloxacin-BW	GQ	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprofloxacin-DRLA	RZ	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprofloxacin-GA	GM	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprofloxacin-PS	FZ	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprofloxacin Sandoz	SZ	MP NP	C1431 C1432 C1572 C1573	14	0
Ciprol 750	QA	MP NP	C1431 C1432 C1572 C1573	14	0
Ciproxin 750	BN	MP NP	C1431 C1432 C1572 C1573 C3680	14	0
GenRx Ciprofloxacin	GX	MP NP	C1431 C1432 C1572 C1573	14	0
Loxip 750	DO	MP NP	C1431 C1432 C1572 C1573	14	0
Ear drops 3 mg (as hydrochloride) per mL, 5 mL	Application to the ear	Ciloxan	AQ	MP NP	C2615 C3191 C3192	1	1
Eye drops 3 mg (as hydrochloride) per mL, 5 mL	Application to the eye	CiloQuin	IQ	MP	C1031	2	0
AO	C3830	2	0
Ciloxan	AQ	MP	C1031	2	0
AO	C3830	2	0
Cisplatin	I.V. injection 50 mg in 50 mL	Injection	Hospira Pty Limited	HH	MP	See Note 3	See Note 3	D
Pfizer Australia Pty Ltd	PF	MP	See Note 3	See Note 3	D
I.V. injection 100 mg in 100 mL	Injection	Cisplatin Ebewe	SZ	MP	See Note 3	See Note 3	D
Hospira Pty Limited	HH	MP	See Note 3	See Note 3	D
Pfizer Australia Pty Ltd	PF	MP	See Note 3	See Note 3	D
Citalopram	Tablet 10 mg (as hydrobromide)	Oral	Celapram	AF	MP NP	C1211	28	5
Tablet 20 mg (as hydrobromide)	Oral	APO-Citalopram	TX	MP NP	C1211	28	5
Auro-Citalopram 20	DO	MP NP	C1211	28	5
Celapram	AF	MP NP	C1211	28	5
Celica	RA	MP NP	C1211	28	5
Chem mart Citalopram	CH	MP NP	C1211	28	5
Ciazil	GM	MP NP	C1211	28	5
Cipramil	LU	MP NP	C1211	28	5
Citalopram 20	CR	MP NP	C1211	28	5
Citalopram-GA	GN	MP NP	C1211	28	5
Citalopram generichealth	GQ	MP NP	C1211	28	5
Citalopram Pfizer	FZ	MP NP	C1211	28	5
Citalopram Sandoz	SZ	MP NP	C1211	28	5
GenRx Citalopram	GX	MP NP	C1211	28	5
Pharmacor Citalo 20	MI	MP NP	C1211	28	5
Talam	QA	MP NP	C1211	28	5
Terry White Chemists Citalopram	TW	MP NP	C1211	28	5
Tablet 40 mg (as hydrobromide)	Oral	APO-Citalopram	TX	MP NP	C1211	28	5
Auro-Citalopram 40	DO	MP NP	C1211	28	5
Celapram	AF	MP NP	C1211	28	5
Citalopram Pfizer	FZ	MP NP	C1211	28	5
Citalopram Sandoz	SZ	MP NP	C1211	28	5
GenRx Citalopram	GX	MP NP	C1211	28	5
Citrulline with carbohydrate	Sachets of oral powder 4 g containing 1 g citrulline, 30 (Citrulline 1000 Amino Acid Supplement)	Oral	Citrulline 1000 Amino Acid Supplement	VF	MP NP	C3679	4	5
Cladribine	Injection 10 mg in 5 mL	Injection	Litak	OA	MP	C3180	See Note 3	See Note 3	D
Solution for I.V. infusion 10 mg in 10 mL single use vial	Injection	Leustatin	JC	MP	C3180	See Note 3	See Note 3	D
Clarithromycin	Tablet 250 mg	Oral	APO-Clarithromycin	TX	MP NP	14	1
Chem mart Clarithromycin	CH	MP NP	14	1
Clarac	GM	MP NP	14	1
Clarihexal	SZ	MP NP	14	1
Clarithro 250	QA	MP NP	14	1
Clarithromycin-PS	FZ	MP NP	14	1
GenRx Clarithromycin	GX	MP NP	14	1
Kalixocin	AF	MP NP	14	1
Klacid	AB	MP NP	14	1
Terry White Chemists Clarithromycin	TW	MP NP	14	1
Klacid	AB	MP See Note 1	C1434 C3325	100	2	C
Tablet 500 mg	Oral	Klacid	AB	MP See Note 1	C1434 C3325	100	2	PB
Powder for oral liquid 250 mg per 5 mL, 50 mL	Oral	Klacid	AB	MP NP	C3016 C3017	1	0
Clindamycin	Capsule 150 mg (as hydrochloride)	Oral	Cleocin	FZ	MP NP MW PDP	C1145	24	0
Dalacin C	PF	MP NP MW PDP	C1145	24	0
Clodronic Acid	Capsule containing 400 mg sodium clodronate (as tetrahydrate)	Oral	Bonefos	BN	MP NP	C1035 C1205 C1233	100	2
Tablet containing 800 mg sodium clodronate (as tetrahydrate)	Oral	Bonefos 800 mg	BN	MP NP	C1035 C1205 C1233	60	2
Clomiphene	Tablet containing clomiphene citrate 50 mg	Oral	Clomid	SW	MP	C1026 C1267	10	5
Serophene	SG	MP	C1026 C1267	10	5
Clomipramine	Tablet containing clomipramine hydrochloride 25 mg	Oral	Anafranil 25	NV	MP NP	C1041 C1241 C1287	50	2
Chem mart Clomipramine	CH	MP NP	C1041 C1241 C1287	50	2
GenRx Clomipramine	GX	MP NP	C1041 C1241 C1287	50	2
Placil	AF	MP NP	C1041 C1241 C1287	50	2
Terry White Chemists Clomipramine	TW	MP NP	C1041 C1241 C1287	50	2
Clonazepam	Tablet 500 micrograms	Oral	Paxam 0.5	AF	MP NP	C1574 C3657 C3658	P3658	100	0
Rivotril	RO	MP NP	C1574 C3657 C3658	P3658	100	0
Paxam 0.5	AF	MP NP	C1574 C3657 C3658	P3657	100	3
Rivotril	RO	MP NP	C1574 C3657 C3658	P3657	100	3
Paxam 0.5	AF	MP NP	C1574 C3657 C3658	P1574	200	2
Rivotril	RO	MP NP	C1574 C3657 C3658	P1574	200	2
Tablet 2 mg	Oral	Paxam 2	AF	MP NP	C1574 C3657 C3658	P3658	100	0
Rivotril	RO	MP NP	C1574 C3657 C3658	P3658	100	0
Paxam 2	AF	MP NP	C1574 C3657 C3658	P3657	100	3
Rivotril	RO	MP NP	C1574 C3657 C3658	P3657	100	3
Paxam 2	AF	MP NP	C1574 C3657 C3658	P3657	200	2
Rivotril	RO	MP NP	C1574 C3657 C3658	P1574	200	2
Oral liquid 2.5 mg per mL, 10 mL	Oral	Rivotril	RO	MP NP	C1574 C3657 C3658	P1574 P3658	2	0
RO	MP NP	C1574 C3657 C3658	P3657	2	3
Injection 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent)	Injection	Rivotril	RO	MP NP	C1093	5	0
Clonidine	Tablet containing clonidine hydrochloride 100 micrograms	Oral	Catapres 100	BY	MP NP	100	5
Tablet containing clonidine hydrochloride 150 micrograms	Oral	Catapres	BY	MP NP	100	5
Clopidogrel	Tablet 75 mg (as hydrogen sulfate)	Oral	APO-Clopidogrel	TX	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
Chem mart Clopidogrel	CH	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
Clopidogrel RBX	RA	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
Clopidogrel Sandoz	SZ	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
Clopidogrel Winthrop	WA	MP NP	C1719 C1720 C1721 C1722 C1723 C1724 C3146 C3879	28	5
Iscover	BQ	MP NP	C1719 C1720 C1721 C1722 C1723 C1724 C3146 C3879	28	5
Piax	AF	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
Plavicor 75	MI	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
Plavix	SW	MP NP	C1719 C1720 C1721 C1722 C1723 C1724 C3146 C3879	28	5
Terry White Chemists Clopidogrel	TW	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
Tablet 75 mg (as besilate)	Oral	Clopidogrel Actavis	TA	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
Clopidogrel-GA	GM	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
Clopidogrel GH	GQ	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
Clopidogrel-PS	FZ	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
Clovix 75	QA	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
STADA Clopidogrel	TD	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
Tablet 75 mg	Oral	Clopidogrel-DRLA	RZ	MP NP	C1719 C1720 C1721 C1722 C1723 C1724	28	5
Clopidogrel with aspirin	Tablet 75 mg (as hydrogen sulfate)-100 mg	Oral	Clopidogrel Winthrop plus aspirin	WA	MP NP	C1722 C3219 C3880	30	5
CoPlavix	SW	MP NP	C1722 C3219 C3880	30	5
DuoCover	BQ	MP NP	C1722 C3219 C3880	30	5
Clostridium Botulinum Type A Toxin—haemagglutinin Complex	Lyophilised powder for I.M. injection 300 units	Injection	Dysport	IS	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Lyophilised powder for I.M. injection 500 units	Injection	Dysport	IS	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Clozapine	Tablet 25 mg	Oral	Clopine 25	HH	MP See Note 1	C1826 C1827 C3326 C3327	100	0	D
Clozaril 25	NV	MP See Note 1	C1826 C1827 C3326 C3327	100	0	D
Tablet 50 mg	Oral	Clopine 50	HH	MP See Note 1	C1826 C1827 C3326 C3327	100	0	D
Tablet 100 mg	Oral	Clopine 100	HH	MP See Note 1	C1826 C1827 C3326 C3327	100	0	D
Clozaril 100	NV	MP See Note 1	C1826 C1827 C3326 C3327	100	0	D
Tablet 200 mg	Oral	Clopine 200	HH	MP See Note 1	C1826 C1827 C3326 C3327	100	0	D
Oral liquid 50 mg per mL, 100 mL	Oral	Clopine Suspension	HH	MP See Note 1	C1826 C1827 C3326 C3327	1	0	D
Coal Tar - Prepared	Gel 10 mg per g, 100 mL	Application	Exorex	GM	MP NP	1	2
Codeine	Tablet containing codeine phosphate 30 mg	Oral	Fawns and McAllan Proprietary Limited	FM	MP NP PDP	20	0
Codeine with Paracetamol	Tablet containing codeine phosphate 30 mg with paracetamol 500 mg	Oral	APO- Paracetamol/Codeine 500/30	TX	MP NP PDP	20	0
Codalgin Forte	FM	MP NP PDP	20	0
Codapane Forte	AL	MP NP PDP	20	0
Comfarol Forte	SZ	MP NP PDP	20	0
Panadeine Forte	SW	MP NP PDP	20	0
Prodeine Forte	AV	MP NP PDP	20	0
APO- Paracetamol/Codeine 500/30	TX	MP NP	P2064	60	0
Codalgin Forte	FM	MP NP	P2064	60	0
Codapane Forte	AL	MP NP	P2064	60	0
Comfarol Forte	SZ	MP NP	P2064	60	0
Panadeine Forte	SW	MP NP	P2064	60	0
Prodeine Forte	AV	MP NP	P2064	60	0
Colchicine	Tablet 500 micrograms	Oral	Colgout	AS	MP NP	30	5
Lengout	LN	MP NP	30	5
Colestipol	Oral powder, sachets containing colestipol hydrochloride 5 g, 120	Oral	Colestid	PF	MP NP	1	5
MP	P3035	1	11
Corifollitropin Alfa	Solution for injection 100 micrograms in 0.5 mL single dose pre-filled syringe	Injection	Elonva	MK	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3	D
Solution for injection 150 micrograms in 0.5 mL single dose pre-filled syringe	Injection	Elonva	MK	MP See Note 1	See Note 3	See Note 3	See Note 3	See Note 3

Continuation of initial treatment as systemic monotherapy (other than methotrexate), in a Biological Treatment Cycle, by a dermatologist for adults 18 years and over who have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot and who, qualifying under the criteria specified above, have previously been issued with an authority prescription for initial treatment with ustekinumab for a period of less than 28 weeks, and where approval of the application would enable the patient to complete a course of 28 weeks of treatment in total	Compliance with Written or Telephone Authority Required procedures
C3789	P3789	Chronic plaque psoriasis (whole body) — initial treatment 2 Initial treatment, or recommencement of treatment, with ustekinumab as systemic monotherapy (other than methotrexate), within an ongoing Biological Treatment Cycle, by a dermatologist for adults 18 years and over who: (a) have a documented history of severe chronic plaque psoriasis; and (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and (c) have not failed PBS-subsidised therapy with ustekinumab for the treatment of this condition in the current Treatment Cycle; and where biological agent means adalimumab, etanercept, infliximab or ustekinumab; and where a Biological Treatment Cycle is a period of treatment with successive biological agents which commences when an eligible patient (one who has not received PBS-subsidised treatment with a biological agent for chronic plaque psoriasis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 biological agent, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with 3 biological agents, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: patients who have previously demonstrated a response to PBS-subsidised treatment with ustekinumab within this Treatment Cycle are only eligible to recommence therapy with this drug within this same cycle, following a break in therapy, where evidence of a response to their most recent course of PBS-subsidised ustekinumab treatment was submitted to the Chief Executive Medicare within 1 month of cessation of that treatment; the application for authorisation is made in writing and includes a completed copy of the appropriate Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form which includes the following: (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition; and (ii) details of prior biological agent treatment, including dosage, date and duration of treatment; a course of initial treatment within an ongoing Treatment Cycle is limited to a maximum of 28 weeks of treatment	Compliance with Written Authority Required procedures
Continuation of initial treatment, or of a course which recommences treatment, with ustekinumab as systemic monotherapy (other than methotrexate), within an ongoing Biological Treatment Cycle, by a dermatologist for adults 18 years and over who have a documented history of severe chronic plaque psoriasis and who, qualifying under the criteria specified above, have previously been issued with an authority prescription for initial treatment or recommencement of treatment with this drug for a period of less than 28 weeks, and where approval of the application would enable the patient to complete a course of 28 weeks of treatment in total	Compliance with Written or Telephone Authority Required procedures
C3790	P3790	Chronic plaque psoriasis (face, hand, foot) — initial treatment 2 Initial treatment, or recommencement of treatment, with ustekinumab as systemic monotherapy (other than methotrexate), within an ongoing Biological Treatment Cycle, by a dermatologist for adults 18 years and over who: (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and (c) have not failed PBS-subsidised therapy with ustekinumab for the treatment of this condition in the current Treatment Cycle; and where biological agent means adalimumab, etanercept, infliximab or ustekinumab; and where a Biological Treatment Cycle is a period of treatment with successive biological agents which commences when an eligible patient (one who has not received PBS-subsidised treatment with a biological agent for chronic plaque psoriasis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 biological agent, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with 3 biological agents, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: patients who have previously demonstrated a response to PBS-subsidised treatment with ustekinumab within this Treatment Cycle are only eligible to recommence therapy with this drug within this same cycle, following a break in therapy, where evidence of a response to their most recent course of PBS-subsidised ustekinumab treatment was submitted to the Chief Executive Medicare within 1 month of cessation of that treatment; the application for authorisation is made in writing and includes a completed copy of the appropriate Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form which includes the following: (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition; and (ii) details of prior biological agent treatment, including dosage, date and duration of treatment; a course of initial treatment within an ongoing Treatment Cycle is limited to a maximum of 28 weeks of treatment	Compliance with Written Authority Required procedures
Continuation of initial treatment, or of a course which recommences treatment, with ustekinumab as systemic monotherapy (other than methotrexate), within an ongoing Biological Treatment Cycle, by a dermatologist for adults 18 years and over who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, and who, qualifying under the criteria specified above, have previously been issued with an authority prescription for initial treatment or recommencement of treatment with this drug for a period of less than 28 weeks, and where approval of the application would enable the patient to complete a course of 28 weeks of treatment in total	Compliance with Written or Telephone Authority Required procedures
C3791	P3791	Chronic plaque psoriasis (whole body) — continuing treatment Continuing treatment as systemic monotherapy (other than methotrexate), within an ongoing Biological Treatment Cycle, by a dermatologist for adults 18 years and over: (a) who have a documented history of severe chronic plaque psoriasis; and (b) whose most recent course of PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle was with ustekinumab; and (c) who have demonstrated an adequate response to their most recent course of treatment with ustekinumab; and where biological agent means adalimumab, etanercept, infliximab or ustekinumab; and where a Biological Treatment Cycle is a period of treatment with successive biological agents which commences when an eligible patient (one who has not received PBS-subsidised treatment with a biological agent for chronic plaque psoriasis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 biological agent, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with 3 biological agents, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: an adequate response to ustekinumab treatment is defined as a Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle; the PASI assessment submitted to demonstrate response is performed on the same affected body area assessed to establish the baseline value; the PASI assessment of response is made after at least 12 weeks of treatment, in the case of a 28-week initial treatment course, or is conducted within 4 weeks prior to completion of the course, in the case of a 24-week treatment course, and is submitted to the Chief Executive Medicare no later than 1 month from the date of completion of the course of treatment; where an assessment of the patient's response to a course of PBS-subsidised treatment is not undertaken and submitted to the Chief Executive Medicare within the timeframes specified above, the patient will be deemed to have failed to respond to treatment with ustekinumab; the application for authorisation is made in writing and includes a completed copy of the appropriate Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form which includes the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition; the most recent PASI assessment is no more than 1 month old at the time of application; a course of continuing treatment within an ongoing Treatment Cycle is limited to a maximum of 24 weeks of treatment	Compliance with Written Authority Required procedures
Continuing treatment as systemic monotherapy (other than methotrexate), within an ongoing Biological Treatment Cycle, by a dermatologist for adults 18 years and over who have a documented history of severe chronic plaque psoriasis and who, qualifying under the criteria specified above, have previously been issued with an authority prescription for continuing treatment with ustekinumab for a period of less than 24 weeks, and where approval of the application would enable the patient to complete a course of 24 weeks of treatment in total	Compliance with Written or Telephone Authority Required procedures
C3792	P3792	Chronic plaque psoriasis (face, hand, foot) — continuing treatment Continuing treatment as systemic monotherapy (other than methotrexate), within an ongoing Biological Treatment Cycle, by a dermatologist for adults 18 years and over: (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and (b) whose most recent course of PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle was with ustekinumab; and (c) who have demonstrated an adequate response to their most recent course of treatment with ustekinumab; and where biological agent means adalimumab, etanercept, infliximab or ustekinumab; and where a Biological Treatment Cycle is a period of treatment with successive biological agents which commences when an eligible patient (one who has not received PBS-subsidised treatment with a biological agent for chronic plaque psoriasis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 biological agent, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with 3 biological agents, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: an adequate response to ustekinumab treatment is defined as the plaque or plaques assessed prior to biological agent treatment showing: (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value; the PASI assessment submitted to demonstrate response is performed on the same affected body area assessed to establish the baseline value; the PASI assessment of response is made after at least 12 weeks of treatment, in the case of a 28-week initial treatment course, or is conducted within 4 weeks prior to completion of the course, in the case of a 24-week treatment course, and is submitted to the Chief Executive Medicare no later than 1 month from the date of completion of the course of treatment; where an assessment of the patient's response to a course of PBS-subsidised treatment is not undertaken and submitted to the Chief Executive Medicare within the timeframes specified above, the patient will be deemed to have failed to respond to treatment with ustekinumab; the application for authorisation is made in writing and includes a completed copy of the appropriate Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form which includes the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition; the most recent PASI assessment is no more than 1 month old at the time of application; a course of continuing treatment within an ongoing Treatment Cycle is limited to a maximum of 24 weeks of treatment	Compliance with Written Authority Required procedures
Continuing treatment as systemic monotherapy (other than methotrexate), within an ongoing Biological Treatment Cycle, by a dermatologist for adults 18 years and over who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, and who, qualifying under the criteria specified above, have previously been issued with an authority prescription for continuing treatment with ustekinumab for a period of less than 24 weeks, and where approval of the application would enable the patient to complete a course of 24 weeks of treatment in total	Compliance with Written or Telephone Authority Required procedures
Valaciclovir	C1494	Where the patient is receiving treatment at/from a private hospital Prophylaxis of cytomegalovirus infection and disease following renal transplantation in patients at risk of cytomegalovirus disease	Compliance with Written or Telephone Authority Required procedures
C3419	Where the patient is receiving treatment at/from a public hospital Prophylaxis of cytomegalovirus infection and disease following renal transplantation in patients at risk of cytomegalovirus disease	Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3419
C3622	P3622	Treatment of patients with herpes zoster within 72 hours of the onset of the rash	Compliance with Authority Required procedures - Streamlined Authority Code 3622
C3623	P3623	Suppressive therapy of moderate to severe recurrent genital herpes, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis	Compliance with Authority Required procedures - Streamlined Authority Code 3623
C3624	P3624	Episodic treatment of moderate to severe recurrent genital herpes, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis	Compliance with Authority Required procedures - Streamlined Authority Code 3624
C3631	P3631	Herpes zoster ophthalmicus	Compliance with Authority Required procedures - Streamlined Authority Code 3631
C3632	P3632	Moderate to severe initial genital herpes	Compliance with Authority Required procedures - Streamlined Authority Code 3632
Valganciclovir	C1620	Where the patient is receiving treatment at/from a private hospital Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome;	Compliance with Written or Telephone Authority Required procedures
C1964	Where the patient is receiving treatment at/from a private hospital Prophylaxis of cytomegalovirus infection and disease in solid organ transplant patients at risk of cytomegalovirus disease.	Compliance with Written or Telephone Authority Required procedures
C3420	Where the patient is receiving treatment at/from a public hospital Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome	Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3420
C3421	Where the patient is receiving treatment at/from a public hospital Prophylaxis of cytomegalovirus infection and disease in solid organ transplant patients at risk of cytomegalovirus disease	Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3421
Valine with carbohydrate	C1220	Maple syrup urine disease
Valsartan with hydrochlorothiazide	C3307	Hypertension in a patient who is not adequately controlled with either of the drugs in the combination
Vancomycin	C1091	P1091	Endophthalmitis
C1302	P1302	Prophylaxis of endocarditis in patients hypersensitive to penicillin
C1464	P1464	Use initiated in a hospital for infections where vancomycin hydrochloride is an appropriate antibiotic
C1701	Antibiotic associated pseudomembranous colitis due to Clostridium difficile which is unresponsive to metronidazole	Compliance with Authority Required procedures
C1702	Antibiotic associated pseudomembranous colitis due to Clostridium difficile where there is intolerance to metronidazole	Compliance with Authority Required procedures
Varenicline	C2774	Commencement of short-term, sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program, and where details of the program are specified in the authority application	Compliance with Authority Required procedures
C2775	Commencement of short-term, sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the same consultation at which the authority application is made, and where details of the program are specified in the authority application	Compliance with Authority Required procedures
C3670	P3670	Continuation of short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has previously been issued with an authority prescription for this drug and who is enrolled in a comprehensive support and counselling program	Compliance with Authority Required procedures
C3671	P3671	Completion of short-term sole PBS-subsidised therapy as an aid to achieving long-term abstinence after completion of an initial 12-week PBS-subsidised course in a patient who has ceased smoking, and who is enrolled in a comprehensive support and counselling program	Compliance with Authority Required procedures
Venlafaxine	C1211	Major depressive disorders
Verteporfin	C3860	Initial treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration, as diagnosed by fluorescein angiography, in a patient with a baseline visual acuity equal to or better than 6/60 (20/200), where the patient has not previously received PBS-subsidised treatment with verteporfin in the eye for which treatment is being sought, and where the authority application includes a completed copy of the appropriate Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form and a copy of the fluorescein angiogram demonstrating that the CNV is predominantly (greater than or equal to 50%) classic	Compliance with Written Authority Required procedures
Initial treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration, as diagnosed by fluorescein angiography, in a patient with a baseline visual acuity equal to or better than 6/60 (20/200), where the patient has not previously received PBS-subsidised treatment with verteporfin in the eye for which treatment is being sought, and where the authority application includes a completed copy of the appropriate Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form and a copy of the fluorescein angiogram demonstrating that the CNV is predominantly (greater than or equal to 50%) classic, is submitted to the Chief Executive Medicare by facsimile prior to contact by telephone and is resubmitted to the Chief Executive Medicare by post after the application has been authorised	Compliance with Telephone Authority Required procedures
C3861	Initial PBS-subsidised treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to macular degeneration, where: (a) the patient has been authorised by the Angiogram Review Panel to receive treatment with verteporfin in the same eye under the Medicare Benefits Scheme (MBS) Visudyne Therapy Program and has received no more than 14 such treatments; and (b) the authority application includes: (i) a completed copy of the appropriate Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form which includes the date of review by the Angiogram Review Panel and the number of treatments administered in that eye under the MBS Visudyne Therapy Program; and (ii) a copy of the fluorescein angiogram demonstrating that the CNV is predominantly (greater than or equal to 50%) classic	Compliance with Written Authority Required procedures
Initial PBS-subsidised treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to macular degeneration, where: (a) the patient has been authorised by the Angiogram Review Panel to receive treatment with verteporfin in the same eye under the Medicare Benefits Scheme (MBS) Visudyne Therapy Program and has received no more than 14 such treatments; and (b) the authority application includes: (i) a completed copy of the appropriate Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form which includes the date of review by the Angiogram Review Panel and the number of treatments administered in that eye under the MBS Visudyne Therapy Program; and (ii) a copy of the fluorescein angiogram demonstrating that the CNV is predominantly (greater than or equal to 50%) classic; and (c) the authority application is submitted to the Chief Executive Medicare by facsimile prior to contact by telephone and is resubmitted to the Chief Executive Medicare by post after the application has been authorised	Compliance with Telephone Authority Required procedures
C3795	Continuing treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation due to macular degeneration, where: (a) the patient has previously been granted an authority prescription for verteporfin for treatment of the same eye; and (b) the patient has previously received no more than 14 subsidised treatments with verteporfin in that eye, treatments administered under the MBS Visudyne Therapy Program and treatments administered under the PBS included; and (c) a course of treatment abandoned prior to completion of the laser activation step but after infusion of verteporfin is not regarded to be a subsidised treatment for the purposes of (b) above, provided that the Chief Executive Medicare has been notified and advised of the reason for the abandonment	Compliance with Written or Telephone Authority Required procedures
Vigabatrin	C1426	Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	Compliance with Authority Required procedures - Streamlined Authority Code 1426
Vildagliptin	C3540	Treatment of type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient in whom a combination of metformin and a sulfonylurea is contraindicated or not tolerated, and: (a) whose glycosylated haemoglobin (HbA1c) prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 is greater than 7%, despite treatment with either metformin or a sulfonylurea; or (b) as an alternative to HbA1c level measurement in the case of patients who have clinical conditions with reduced red blood cell survival (including haemolytic anaemias and haemoglobinopathies) and/or who have had red cell transfusion within the previous 3 months — where blood glucose monitoring over a 2 week period prior to initiation of a gliptin, a glitazone or a glucagon-like peptide-1 shows blood glucose levels greater than 10 mmol per L in more than 20% of tests, despite treatment with either metformin or a sulfonylurea; and where the qualifying HbA1c level and date of measurement, or the results of the blood glucose monitoring, whichever are applicable in the circumstances, are documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated; and where the qualifying HbA1c level and the results of the blood glucose monitoring are no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated	Compliance with Authority Required procedures - Streamlined Authority Code 3540
Vildagliptin with metformin	C3543	Treatment of type 2 diabetes in a patient in whom a combination of metformin and a sulfonylurea is contraindicated or not tolerated, and: (a) whose glycosylated haemoglobin (HbA1c) prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 is greater than 7%, despite treatment with metformin; or (b) as an alternative to HbA1c level measurement in the case of patients who have clinical conditions with reduced red blood cell survival (including haemolytic anaemias and haemoglobinopathies) and/or who have had red cell transfusion within the previous 3 months — where blood glucose monitoring over a 2 week period prior to initiation of a gliptin, a glitazone or a glucagon-like peptide-1 shows blood glucose levels greater than 10 mmol per L in more than 20% of tests, despite treatment with metformin; and where the qualifying HbA1c level and date of measurement, or the results of the blood glucose monitoring, whichever are applicable in the circumstances, are documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated; and where the qualifying HbA1c level and the results of the blood glucose monitoring are no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated	Compliance with Authority Required procedures - Streamlined Authority Code 3543
C3686	Continuation of therapy in type 2 diabetes mellitus in a patient who has previously received and been stabilised on a PBS-subsidised regimen of oral diabetic medicines which includes metformin and vildagliptin.	Compliance with Authority Required procedures - Streamlined Authority Code 3686
Vinorelbine	C1194	Locally advanced or metastatic non-small cell lung cancer	Compliance with Authority Required procedures
C3890	Locally advanced or metastatic non-small cell lung cancer	Compliance with Authority Required procedures - Streamlined Authority Code 3890
C3907	Advanced breast cancer after failure of prior therapy which includes an anthracycline	Compliance with Authority Required procedures - Streamlined Authority Code 3907
Vitamins, minerals and trace elements with carbohydrate	C3301	Infants and children whose vitamin and mineral intake is insufficient due to a specific diagnosis requiring a highly restrictive therapeutic diet, and whose vitamin, mineral and trace element needs cannot be adequately met with other proprietary vitamin and mineral preparations	Compliance with Authority Required procedures
Voriconazole	C3061	For the treatment and maintenance therapy of definite or probable invasive aspergillosis in immunocompromised patients	Compliance with Authority Required procedures
C3062	For the treatment and maintenance therapy of serious fungal infections caused by Scedosporium species or Fusarium species	Compliance with Authority Required procedures
C3065	For the treatment and maintenance therapy of serious Candida infections where treatment with fluconazole has failed	Compliance with Authority Required procedures
C3066	For the treatment and maintenance therapy of serious Candida infections where treatment with fluconazole is not tolerated	Compliance with Authority Required procedures
C3297	For the treatment and maintenance therapy of serious Candida infections where the causative species is not susceptible to fluconazole	Compliance with Authority Required procedures
C3298	For the treatment and maintenance therapy of other serious invasive mycosis	Compliance with Authority Required procedures
Whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose	C1596	Infants and young children with chronic renal failure requiring treatment with a low protein and a low phosphorus diet, or a low protein, a low phosphorus and a low potassium diet	Compliance with Authority Required procedures
Whey protein formula supplemented with amino acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose	C1596	Infants and young children with chronic renal failure requiring treatment with a low protein and a low phosphorus diet, or a low protein, a low phosphorus and a low potassium diet	Compliance with Authority Required procedures
Zidovudine	C3586	Where the patient is receiving treatment at/from a private hospital Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease	Compliance with Written or Telephone Authority Required procedures
C3587	Where the patient is receiving treatment at/from a private hospital Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection	Compliance with Written or Telephone Authority Required procedures
C3588	Where the patient is receiving treatment at/from a public hospital Initial treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease	Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3588
C3589	Where the patient is receiving treatment at/from a public hospital Continuing treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection	Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3589
Ziprasidone	C1589	Schizophrenia	Compliance with Authority Required procedures - Streamlined Authority Code 1589
C3084	Monotherapy, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder	Compliance with Authority Required procedures - Streamlined Authority Code 3084
Zoledronic acid	C1035	Where the patient is receiving treatment at/from a private hospital Bone metastases from breast cancer	Compliance with Written or Telephone Authority Required procedures
C1233	Where the patient is receiving treatment at/from a private hospital Multiple myeloma	Compliance with Written or Telephone Authority Required procedures
C1500	Where the patient is receiving treatment at/from a private hospital Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy	Compliance with Written or Telephone Authority Required procedures
C3290	Symptomatic Paget disease of bone, and where PBS-subsidised treatment is limited to 1 dose each year	Compliance with Authority Required procedures
C3341	Where the patient is receiving treatment at/from a public hospital Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy	Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3341
C3342	Where the patient is receiving treatment at/from a public hospital Multiple myeloma	Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3342
C3343	Where the patient is receiving treatment at/from a public hospital Bone metastases from breast cancer	Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3343
C3945	Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy with a bone mineral density T-score of -1.5 or less, and where the duration and dose of corticosteroid therapy, and the date, site (femoral neck or lumbar spine) and score of the qualifying bone mineral density measurement, are documented in the patient's medical records when treatment is initiated, and where PBS-subsidised treatment is limited to 1 dose per patient each year	Compliance with Authority Required procedures - Streamlined Authority Code 3945
C3946	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in a patient with fracture due to minimal trauma, where the fracture has been demonstrated radiologically and the year of plain x-ray or computed tomography scan or magnetic resonance imaging scan is documented in the patient's medical records when treatment is initiated, provided that if the fracture is a vertebral fracture, there is a 20% or greater reduction in height of the anterior or mid portion of the affected vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body, and where PBS-subsidised treatment is limited to 1 dose per patient per year	Compliance with Authority Required procedures - Streamlined Authority Code 3946
C3947	Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a bone mineral density T-score of -3.0 or less, where the date, site (femoral neck or lumbar spine) and score of the qualifying bone mineral density measurement are documented in the patient's medical records when treatment is initiated, and where PBS-subsidised treatment is limited to 1 dose per patient each year	Compliance with Authority Required procedures - Streamlined Authority Code 3947
C4051	Where the patient is receiving treatment at/from a private hospital Bone metastases from castration-resistant prostate cancer	Compliance with Written or Telephone Authority Required procedures
C4052	Where the patient is receiving treatment at/from a public hospital Bone metastases from castration-resistant prostate cancer	Compliance with Written or Telephone Authority Required procedures – Streamlined Authority Code 4052
Zolmitriptan	C3280	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics.	Compliance with Authority Required procedures
C3281	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where adverse events have occurred with other suitable PBS-listed drugs	Compliance with Authority Required procedures
C3282	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where drug interactions have occurred with other suitable PBS-listed drugs	Compliance with Authority Required procedures
C3283	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where drug interactions are expected to occur with other suitable PBS-listed drugs	Compliance with Authority Required procedures
C3284	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where transfer to another suitable PBS-listed drug would cause patient confusion resulting in problems with compliance	Compliance with Authority Required procedures
C3285	Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics, and where transfer to another suitable PBS-listed drug is likely to result in adverse clinical consequences	Compliance with Authority Required procedures
Zonisamide	C2664	Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs	Compliance with Authority Required procedures - Streamlined Authority Code 2664

Note The name of the listed drug is included in this table to assist in identifying the circumstances applying to the pharmaceutical benefits that have a particular drug.

Part 2 General statement for lipid-lowering drugs

1 Criteria for eligibility for lipid-lowering drugs

(1) The criteria for patient eligibility for lipid-lowering drugs are that:

(a) the patient:

(i) is in a very high risk category; and

(ii) dietary therapy will commence simultaneously with the drug therapy; and

(iii) dietary therapy will continue concurrently with the drug therapy and will be reviewed at least annually; or

(b) the patient:

(i) has been assessed in accordance with clause 2 and meets the lipid levels for PBS subsidy set out in clause 3; and

(ii) dietary therapy will continue concurrently with the drug therapy and will be reviewed at least annually.

Note Patients mentioned in paragraph (b) (i) must be trialled on dietary therapy prior to commencing the drug therapy — see the flowchart in clause 2.

(2) In this clause, a patient is in a very high risk category if the patient has:

(a) coronary heart disease that has become symptomatic; or

(b) cerebrovascular disease that has become symptomatic; or

(c) peripheral vascular disease that has become symptomatic; or

(d) diabetes mellitus with microalbuminuria where the patient has:

(i) a urinary albumin excretion rate of >20 mcg/min; or

(ii) a urinary albumin to creatinine ratio of:

(A) > 2.5 for a male patient; or

(B) > 3.5 for a female patient; or

(e) diabetes mellitus and the patient is:

(i) an Aboriginal or Torres Strait Islander; or

(ii) aged 60 years or over; or

(f) a family history of coronary heart disease that has become symptomatic before the age of 55 years in 2 or more first degree relatives; or

(g) a family history of coronary heart disease that has become symptomatic before the age of 45 years in 1 or more first degree relatives.

2 Assessment of patient

For subparagraph 1 (1) (b) (i), the patient has been assessed as set out in the following flowchart:

3 Lipid levels

(1) For subparagraph 1 (1) (b) (i), a patient meets the lipid levels for PBS subsidy if the patient:

(a) is a kind of patient mentioned for an item in column 2 of the following table; and

(b) has a lipid level, measured by an accredited laboratory, mentioned in column 3 of the table for that item.

Item	Kind of patient	Lipid levels
1	Patient with diabetes mellitus	Total cholesterol > 5.5 mmol/L
2	Aboriginal or Torres Strait Islander patient with hypertension	Either: (a) total cholesterol > 6.5 mmol/L; or (b) total cholesterol > 5.5 mmol/L and HDL cholesterol < 1 mmol/L
3	Patient with HDL cholesterol <1 mmol/L	Total cholesterol > 6.5 mmol/L
4	Patient with: (a) familial hypercholesterolaemia identified by: (i) tendon xanthomas in the patient or a first or second degree relative of the patient; or (i) DNA mutation; or (b) a family history of coronary heart disease which has become symptomatic: (i) before the age of 60 years in 1 or more first degree relatives; or (ii) before the age of 50 years in 1 or more second degree relatives	Either: (a) if the patient is aged 18 years or less at time of treatment initiation — LDL cholesterol > 4 mmol/L; or (b) if patient is aged more than 18 years at time of treatment initiation: (i) LDL cholesterol > 5 mmol/L; or (ii) total cholesterol > 6.5 mmol/L; or (iii) total cholesterol > 5.5 mmol/L and HDL cholesterol < 1 mmol/L
5	Either: (a) male patient aged between 35 and 75 years (inclusive); or (b) female patient, post-menopausal and aged 75 years or less	Either: (a) total cholesterol > 7.5 mmol/L; or (b) triglyceride > 4 mmol/L
6	Any other patient	Either: (a) total cholesterol > 9 mmol/L; or (b) triglyceride > 8 mmol/L

(2) In this clause:

accredited laboratory means:

(a) premises approved under section 23DN of the Health Insurance Act 1973; or

(b) a laboratory accredited in accordance with standards set by the National Pathology Accreditation Advisory Council established under subsection 9 (1) of the National Health Act 1953.

Notes to the National Health (Listing of Pharmaceutical Benefits) Instrument 2010

PB 108 of 2010

Note 1

The National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010) (in force under sections 84AF, 85, 85A, 88 and 101 of the National Health Act 1953) as shown in this compilation is amended as indicated in the Tables below.

Table of Instruments

Title	Date of FRLI registration	Date of commencement	Application, saving or transitional provisions
PB 108 of 2010	30 Nov 2010 (see F2010L03137)	1 Dec 2010
PB 120 of 2010	20 Dec 2010 (see F2010L03303)	1 Jan 2010	—
PB 1 of 2011	28 Jan 2011 (see F2011L00161)	1 Feb 2011	—
PB 11 of 2011	20 Jan 2011 (see F2011L00136)	20 Jan 2011	—
PB 14 of 2011	24 Feb 2011 (see F2011L00302)	1 Mar 2011	—
PB 24 of 2011	28 Mar 2011 (see F2011L00507)	1 Apr 2011	—
PB 31 of 2011	13 Apr 2011 (see F2011L00605)	1 May 2011	—
PB 36 of 2011	26 May 2011 (see F2011L00868)	1 June 2011	—
PB 42 of 2011	15 June 2011 (see F2011L01049)	1 July 2011	—
PB 49 of 2011	28 July 2011 (see F2011L01549)	1 Aug 2011	—
PB 57 of 2011	30 Aug 2011 (see F2011L01773)	1 Sept 2011	—
PB 67 of 2011	29 Sept 2011 (see F2011L01996)	1 Oct 2011	—
PB 74 of 2011	26 Oct 2011 (see F2011L02132)	1 Nov 2011	—
PB 83 of 2011	25 Nov 2011 (see F2011L02477)	1 Dec 2011	—
PB 95 of 2011	30 Nov 2011 (see F2011L02508)	1 Dec 2011	—
PB 96 of 2011	15 Dec 2011 (see F2011L02697)	1 Jan 2012	—
PB 1 of 2012	14 Feb 2012 (see F2012L00288)	1 Mar 2012	—
PB 13 of 2012	30 Mar 2012 (see F2012L00730)	1 Apr 2012	—
PB 27 of 2012	26 Apr 2012 (see F2012L00935)	1 May 2012	—
PB 33 of 2012	8 May 2012 (see F2012L01005)	1 June 2012	—
PB 37 of 2012	15 June 2012 (see F2012L01204)	1 July 2012	—
PB 44 of 2012	25 July 2012 (see F2012L01605)	1 Aug 2012	—
PB 60 of 2012	15 Aug 2012 (see F2012L01683)	Schedule 1: 1 Aug 2012 Schedule 2: 1 Sept 2012	—

Table of Amendments

ad. = added or inserted am. = amended rep. = repealed rs. = repealed and substituted
Provision affected	How affected
Note to s. 4........................... ............................................... ............................................... ...............................................	am. PB 57 of 2011
S. 5........................................	am. PB 83 of 2011
S. 11......................................	am. PB 57 of 2011
S. 12......................................	am. PB 57 of 2011
S. 13......................................	am. PB 57 of 2011
S. 14......................................	am. PB 57 of 2011
S. 20......................................	am. PB 83 of 2011
Schedule 1
Schedule 1...........................	am. PB 120 of 2010; PB 1, 11, 14, 24 31, 36, 42, 49, 57, 67, 74, 83, 95 and 96 of 2011; PB 1, 13, 27, 33, 37, 44 and 60 of 2012
Schedule 3
Schedule 3...........................	am. PB 120 of 2010; PB 1, 14, 24, 31, 36, 42, 49, 57, 67, 83 and 96 of 2011; PB 1, 13, 27, 33, 37, 44 and 60 of 2012
Schedule 4
Schedule 4...........................	am. PB 120 of 2010; PB 1, 11, 14, 24, 31, 36, 42, 49, 57, 67, 74, 83 and 96 of 2011; PB 1, 13, 27, 33, 37, 44 and 60 of 2012